
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-a68b4900.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-0a3f24ce.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3‐tyrosine kinase domain mutations: Prognostic implications of NPM1 co‐mutation - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="67D7131F89B72E431C131F00344795FA.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="blackwellopen">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335293/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Cancer">
<meta name="citation_title" content="Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3‐tyrosine kinase domain mutations: Prognostic implications of NPM1 co‐mutation">
<meta name="citation_author" content="Sankalp Arora">
<meta name="citation_author_institution" content="Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA">
<meta name="citation_author" content="Wei‐Ying Jen">
<meta name="citation_author_institution" content="Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA">
<meta name="citation_author" content="Musa Yilmaz">
<meta name="citation_author_institution" content="Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA">
<meta name="citation_author" content="Indraneel Deshmukh">
<meta name="citation_author_institution" content="Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA">
<meta name="citation_author" content="Jayastu Senapati">
<meta name="citation_author_institution" content="Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA">
<meta name="citation_author" content="Sanam Loghavi">
<meta name="citation_author_institution" content="Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA">
<meta name="citation_author" content="Ghayas C Issa">
<meta name="citation_author_institution" content="Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA">
<meta name="citation_author" content="Nicholas J Short">
<meta name="citation_author_institution" content="Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA">
<meta name="citation_author" content="Tapan M Kadia">
<meta name="citation_author_institution" content="Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA">
<meta name="citation_author" content="Courtney D DiNardo">
<meta name="citation_author_institution" content="Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA">
<meta name="citation_author" content="Gautam Borthakur">
<meta name="citation_author_institution" content="Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA">
<meta name="citation_author" content="Joseph Jabbour">
<meta name="citation_author_institution" content="Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA">
<meta name="citation_author" content="Naveen Pemmaraju">
<meta name="citation_author_institution" content="Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA">
<meta name="citation_author" content="Michael Andreeff">
<meta name="citation_author_institution" content="Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA">
<meta name="citation_author" content="Koichi Takahashi">
<meta name="citation_author_institution" content="Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA">
<meta name="citation_author" content="Kapil Bhalla">
<meta name="citation_author_institution" content="Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA">
<meta name="citation_author" content="Uday Popat">
<meta name="citation_author_institution" content="Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA">
<meta name="citation_author" content="Elizabeth J Shpall">
<meta name="citation_author_institution" content="Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA">
<meta name="citation_author" content="Betul Oran">
<meta name="citation_author_institution" content="Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA">
<meta name="citation_author" content="Hussein A Abbas">
<meta name="citation_author_institution" content="Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA">
<meta name="citation_author" content="Guillermo Garcia‐Manero">
<meta name="citation_author_institution" content="Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA">
<meta name="citation_author" content="Farhad Ravandi">
<meta name="citation_author_institution" content="Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA">
<meta name="citation_author" content="Hagop Kantarjian">
<meta name="citation_author_institution" content="Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA">
<meta name="citation_author" content="Naval Daver">
<meta name="citation_author_institution" content="Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA">
<meta name="citation_publication_date" content="2025 Aug 9">
<meta name="citation_volume" content="131">
<meta name="citation_issue" content="16">
<meta name="citation_firstpage" content="e70032">
<meta name="citation_doi" content="10.1002/cncr.70032">
<meta name="citation_pmid" content="40782343">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335293/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335293/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335293/pdf/CNCR-131-e70032.pdf">
<meta name="description" content="The prognostic impact of Fms‐like tyrosine kinase 3 (FLT3)‐tyrosine kinase domain (TKD) mutation in patients with acute myeloid leukemia (AML) is not well defined. The authors described outcomes of one of the largest cohorts of patients with ...">
<meta name="og:title" content="Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3‐tyrosine kinase domain mutations: Prognostic implications of NPM1 co‐mutation">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="The prognostic impact of Fms‐like tyrosine kinase 3 (FLT3)‐tyrosine kinase domain (TKD) mutation in patients with acute myeloid leukemia (AML) is not well defined. The authors described outcomes of one of the largest cohorts of patients with ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335293/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            
                <a class="ncbi-header__logo-container" href="https://www.ncbi.nlm.nih.gov/">
                    <img alt="
                                  NCBI home page
                              "
                         class="ncbi-header__logo-image"
                         src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" />
                </a>
            

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-testid="searchPanel"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      aria-describedby="search-field-desktop-navigation-help-text"
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only"
                           data-testid="label"
                           for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           data-testid="textInput"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    data-testid="button"
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  role="search">
                <label class="usa-sr-only" for="search-field">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="search" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12335293">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1002/cncr.70032"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/CNCR-131-e70032.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12335293%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12335293/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12335293/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335293/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-blackwellopen.png" alt="Wiley Open Access Collection logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Wiley Open Access Collection" title="Link to Wiley Open Access Collection" shape="default" href="https://doi.org/10.1002/cncr.70032" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Cancer</button></div>. 2025 Aug 9;131(16):e70032. doi: <a href="https://doi.org/10.1002/cncr.70032" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1002/cncr.70032</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Cancer%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cancer%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Cancer%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Cancer%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Outcomes of patients with newly diagnosed acute myeloid leukemia with <em>FLT3</em>‐tyrosine kinase domain mutations: Prognostic implications of <em>NPM1</em> co‐mutation</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Arora%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Sankalp Arora</span></a><div hidden="hidden" id="id1">
<h3>
<span class="name western">Sankalp Arora</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Arora%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sankalp Arora</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jen%20WY%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Wei‐Ying Jen</span></a><div hidden="hidden" id="id2">
<h3>
<span class="name western">Wei‐Ying Jen</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jen%20WY%22%5BAuthor%5D" class="usa-link"><span class="name western">Wei‐Ying Jen</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yilmaz%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Musa Yilmaz</span></a><div hidden="hidden" id="id3">
<h3>
<span class="name western">Musa Yilmaz</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yilmaz%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Musa Yilmaz</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Deshmukh%20I%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Indraneel Deshmukh</span></a><div hidden="hidden" id="id4">
<h3>
<span class="name western">Indraneel Deshmukh</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Deshmukh%20I%22%5BAuthor%5D" class="usa-link"><span class="name western">Indraneel Deshmukh</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Senapati%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Jayastu Senapati</span></a><div hidden="hidden" id="id5">
<h3>
<span class="name western">Jayastu Senapati</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Senapati%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jayastu Senapati</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Loghavi%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Sanam Loghavi</span></a><div hidden="hidden" id="id6">
<h3>
<span class="name western">Sanam Loghavi</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>3</sup>
</sup>Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Loghavi%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sanam Loghavi</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Issa%20GC%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Ghayas C Issa</span></a><div hidden="hidden" id="id7">
<h3>
<span class="name western">Ghayas C Issa</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Issa%20GC%22%5BAuthor%5D" class="usa-link"><span class="name western">Ghayas C Issa</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Short%20NJ%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Nicholas J Short</span></a><div hidden="hidden" id="id8">
<h3>
<span class="name western">Nicholas J Short</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Short%20NJ%22%5BAuthor%5D" class="usa-link"><span class="name western">Nicholas J Short</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kadia%20TM%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Tapan M Kadia</span></a><div hidden="hidden" id="id9">
<h3>
<span class="name western">Tapan M Kadia</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kadia%20TM%22%5BAuthor%5D" class="usa-link"><span class="name western">Tapan M Kadia</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22DiNardo%20CD%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Courtney D DiNardo</span></a><div hidden="hidden" id="id10">
<h3>
<span class="name western">Courtney D DiNardo</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22DiNardo%20CD%22%5BAuthor%5D" class="usa-link"><span class="name western">Courtney D DiNardo</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Borthakur%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Gautam Borthakur</span></a><div hidden="hidden" id="id11">
<h3>
<span class="name western">Gautam Borthakur</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Borthakur%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Gautam Borthakur</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jabbour%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Joseph Jabbour</span></a><div hidden="hidden" id="id12">
<h3><span class="name western">Joseph Jabbour</span></h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jabbour%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Joseph Jabbour</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pemmaraju%20N%22%5BAuthor%5D" class="usa-link" aria-describedby="id13"><span class="name western">Naveen Pemmaraju</span></a><div hidden="hidden" id="id13">
<h3>
<span class="name western">Naveen Pemmaraju</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pemmaraju%20N%22%5BAuthor%5D" class="usa-link"><span class="name western">Naveen Pemmaraju</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Andreeff%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id14"><span class="name western">Michael Andreeff</span></a><div hidden="hidden" id="id14">
<h3>
<span class="name western">Michael Andreeff</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Andreeff%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Michael Andreeff</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Takahashi%20K%22%5BAuthor%5D" class="usa-link" aria-describedby="id15"><span class="name western">Koichi Takahashi</span></a><div hidden="hidden" id="id15">
<h3>
<span class="name western">Koichi Takahashi</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Takahashi%20K%22%5BAuthor%5D" class="usa-link"><span class="name western">Koichi Takahashi</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bhalla%20K%22%5BAuthor%5D" class="usa-link" aria-describedby="id16"><span class="name western">Kapil Bhalla</span></a><div hidden="hidden" id="id16">
<h3>
<span class="name western">Kapil Bhalla</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bhalla%20K%22%5BAuthor%5D" class="usa-link"><span class="name western">Kapil Bhalla</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Popat%20U%22%5BAuthor%5D" class="usa-link" aria-describedby="id17"><span class="name western">Uday Popat</span></a><div hidden="hidden" id="id17">
<h3>
<span class="name western">Uday Popat</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>4</sup>
</sup>Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Popat%20U%22%5BAuthor%5D" class="usa-link"><span class="name western">Uday Popat</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shpall%20EJ%22%5BAuthor%5D" class="usa-link" aria-describedby="id18"><span class="name western">Elizabeth J Shpall</span></a><div hidden="hidden" id="id18">
<h3>
<span class="name western">Elizabeth J Shpall</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>4</sup>
</sup>Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shpall%20EJ%22%5BAuthor%5D" class="usa-link"><span class="name western">Elizabeth J Shpall</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Oran%20B%22%5BAuthor%5D" class="usa-link" aria-describedby="id19"><span class="name western">Betul Oran</span></a><div hidden="hidden" id="id19">
<h3>
<span class="name western">Betul Oran</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>4</sup>
</sup>Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Oran%20B%22%5BAuthor%5D" class="usa-link"><span class="name western">Betul Oran</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Abbas%20HA%22%5BAuthor%5D" class="usa-link" aria-describedby="id20"><span class="name western">Hussein A Abbas</span></a><div hidden="hidden" id="id20">
<h3>
<span class="name western">Hussein A Abbas</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Abbas%20HA%22%5BAuthor%5D" class="usa-link"><span class="name western">Hussein A Abbas</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Garcia%E2%80%90Manero%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id21"><span class="name western">Guillermo Garcia‐Manero</span></a><div hidden="hidden" id="id21">
<h3>
<span class="name western">Guillermo Garcia‐Manero</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Garcia%E2%80%90Manero%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Guillermo Garcia‐Manero</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ravandi%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id22"><span class="name western">Farhad Ravandi</span></a><div hidden="hidden" id="id22">
<h3>
<span class="name western">Farhad Ravandi</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ravandi%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Farhad Ravandi</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kantarjian%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id23"><span class="name western">Hagop Kantarjian</span></a><div hidden="hidden" id="id23">
<h3>
<span class="name western">Hagop Kantarjian</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kantarjian%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Hagop Kantarjian</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Daver%20N%22%5BAuthor%5D" class="usa-link" aria-describedby="id24"><span class="name western">Naval Daver</span></a><div hidden="hidden" id="id24">
<h3>
<span class="name western">Naval Daver</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Daver%20N%22%5BAuthor%5D" class="usa-link"><span class="name western">Naval Daver</span></a>
</div>
</div>
<sup>2,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="cncr70032-aff-0001">
<sup>
<sup>1</sup>
</sup>Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div id="cncr70032-aff-0002">
<sup>
<sup>2</sup>
</sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div id="cncr70032-aff-0003">
<sup>
<sup>3</sup>
</sup>Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div id="cncr70032-aff-0004">
<sup>
<sup>4</sup>
</sup>Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="author-notes p">
<div class="fn" id="correspondenceTo">
<sup>*</sup><p class="display-inline">

<strong>Correspondence</strong>
, 
Naval Daver, Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA. 
Email: <span>ndaver@mdanderson.org</span>

</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Revised 2025 Jul 6; Received 2025 May 22; Accepted 2025 Jul 8; Issue date 2025 Aug 15.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 The Author(s). <em>Cancer</em> published by Wiley Periodicals LLC on behalf of American Cancer Society.</div>
<p>This is an open access article under the terms of the <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12335293  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40782343/" class="usa-link">40782343</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<section id="cncr70032-sec-0001"><h3 class="pmc_sec_title">Background</h3>
<p>The prognostic impact of Fms‐like tyrosine kinase 3 (<em>FLT3</em>)‐tyrosine kinase domain (TKD) mutation in patients with acute myeloid leukemia (AML) is not well defined. The authors described outcomes of one of the largest cohorts of patients with <em>FLT3</em>‐TKD mutated (<em>FLT3</em>‐TKD<sup>mut</sup>) AML to date.</p></section><section id="cncr70032-sec-0002"><h3 class="pmc_sec_title">Methods</h3>
<p>This retrospective study included patients with newly diagnosed AML who received frontline treatment at The University of Texas MD Anderson Cancer Center from January 2012 to March 2024 divided into two cohorts: <em>FLT3</em>‐TKD<sup>mut</sup> AML and nucleophosmin‐mutated (<em>NPM1</em>
<sup>mut</sup>)/<em>FLT3</em>‐TKD wild‐type (<em>FLT3</em>‐TKD<sup>wt</sup>) AML. Patients with <em>FLT3</em> internal tandem duplication mutations were excluded.</p></section><section id="cncr70032-sec-0003"><h3 class="pmc_sec_title">Results</h3>
<p>In total, 2922 patients were screened, and 250 met inclusion criteria, including 124 patients with <em>FLT3</em>‐TKD<sup>mut</sup> AML and 126 patients with <em>NPM1</em>
<sup>mut</sup>/<em>FLT3</em>‐TKD<sup>wt</sup> AML. In the <em>FLT3</em>‐TKD<sup>mut</sup> cohort (<em>n</em> = 124), intensive chemotherapy was received by 54 patients (44%), with a composite complete remission in 81% and a 3‐year overall survival (OS) rate of 56%. An <em>NPM1</em> mutation was noted in 24 patients (44%) who had improved OS (3‐year OS, 74% vs. 40%; <em>p</em> = .03). Allogeneic stem cell transplantation improved OS in patients who had <em>NPM1</em>
<sup>wt</sup> AML (3‐year OS, 89% vs. 30%; <em>p</em> = .02) but not in those who had an <em>NPM1</em> mutation. Lower intensity therapy was received by 70 patients (56%), with a composite complete remission in 63% and a 3‐year OS rate of 23%. An <em>NPM1</em> mutation was noted in 31 patients (44%) who had improved OS (3‐year OS, 32% vs. 16%; <em>p</em> = .04). Allogeneic stem cell transplantation led to a trend toward improved OS in patients who had <em>NPM1</em>
<sup>wt</sup> AML (3‐year OS, 75% vs. 27%; <em>p</em> = .1) but not in those who had <em>NPM1</em>
<sup>mut</sup> AML. In the <em>NPM1</em>
<sup>mut</sup>/<em>FLT3</em>‐TKD<sup>wt</sup> cohort (<em>n</em> = 126), intensive chemotherapy was received by 46 patients (37%), and lower intensity therapy was received by 80 patients (63%). Compared with the <em>NPM1</em>
<sup>mut</sup>/<em>FLT3</em>‐TKD<sup>mut</sup> cohort, no difference in OS was noted between patients who received intensive chemotherapy and those who received lower intensity therapy.</p></section><section id="cncr70032-sec-0004"><h3 class="pmc_sec_title">Conclusions</h3>
<p>
<em>FLT3‐</em>TKD<sup>mut</sup> AML commonly harbors <em>NPM1</em> co‐mutation, which has key prognostic implications. Lack of <em>NPM1</em> co‐mutation portends a poor prognosis, and allogenic stem cell transplantation should be strongly considered for patients in first remission.</p></section><section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> acute myeloid leukemia, allogeneic stem cell transplantation, 
<em>FLT3</em>‐tyrosine kinase domain (TKD) mutation, Fms‐like tyrosine kinase 3 (<em>FLT3</em>) inhibitors, nucleophosmin (<em>NPM1</em>) mutation, venetoclax</p></section></section><section class="abstract" id="abstract2"><h2>Short abstract</h2>
<p>
<em>FLT3</em>‐tyrosine kinase domain–mutated acute myeloid leukemia commonly harbors <em>NPM1</em> co‐mutation, which has key prognostic implications. Lack of <em>NPM1</em> co‐mutation in <em>FLT3</em>–tyrosine kinase domain–mutated acute myeloid leukemia portends a poor prognosis, and allogeneic stem cell transplantation should be strongly considered in first remission for this group.</p></section><section id="cncr70032-sec-0010"><h2 class="pmc_sec_title">INTRODUCTION</h2>
<p>Fms‐like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase that is selectively expressed in normal hematopoietic stem and progenitor cells in the bone marrow and plays an important role in normal hematopoiesis.<a href="#cncr70032-bib-0001" class="usa-link" aria-describedby="cncr70032-bib-0001">
<sup>1</sup>
</a> Somatic mutations in the <em>FLT3</em> gene leading to constitutive activation of the FLT3 receptor tyrosine kinase occur in about 30%–35% of patients with newly diagnosed (ND) acute myeloid leukemia (AML).<a href="#cncr70032-bib-0002" class="usa-link" aria-describedby="cncr70032-bib-0002">
<sup>2</sup>
</a>, <a href="#cncr70032-bib-0003" class="usa-link" aria-describedby="cncr70032-bib-0003">
<sup>3</sup>
</a> The two main types of FLT3 mutations include internal tandem duplication (ITD) mutations in 25% of patients with ND AML and point mutations in the activation loop of the tyrosine kinase domain (TKD) in 7%–10% of patients with ND AML.<a href="#cncr70032-bib-0004" class="usa-link" aria-describedby="cncr70032-bib-0004">
<sup>4</sup>
</a>, <a href="#cncr70032-bib-0005" class="usa-link" aria-describedby="cncr70032-bib-0005">
<sup>5</sup>
</a>
<em>FLT3</em>‐ITD–mutated (<em>FLT3</em>‐ITD<sup>mut</sup>) AML has been historically associated with proliferative disease phenotype, high relapse rates, and an overall inferior prognosis when treated with conventional chemotherapies, although outcomes have remarkably improved with the introduction of FLT3 inhibitor (FLT3i) drugs, particularly when an FLT3i was added to an intensive chemotherapy (IC) backbone in younger/fit patients.<a href="#cncr70032-bib-0006" class="usa-link" aria-describedby="cncr70032-bib-0006">
<sup>6</sup>
</a>, <a href="#cncr70032-bib-0007" class="usa-link" aria-describedby="cncr70032-bib-0007">
<sup>7</sup>
</a>, <a href="#cncr70032-bib-0008" class="usa-link" aria-describedby="cncr70032-bib-0008">
<sup>8</sup>
</a>, <a href="#cncr70032-bib-0009" class="usa-link" aria-describedby="cncr70032-bib-0009">
<sup>9</sup>
</a>
</p>
<p>In contrast, the prognostic role of <em>FLT3</em>‐TKD<sup>mut</sup> has remained less well defined. In a study of 147 patients with <em>FLT3</em>‐TKD<sup>mut</sup>AML who received IC without an FLT3i drug, the presence of an <em>FLT3</em>‐TKD mutation by itself did not appear to have an effect on overall survival (OS) or event‐free survival (EFS).<a href="#cncr70032-bib-0010" class="usa-link" aria-describedby="cncr70032-bib-0010">
<sup>10</sup>
</a> The prognostic effect was highly co‐mutation–dependent. The presence of an <em>FLT3</em>‐TKD mutation was associated with worse outcomes when co‐occurring with unfavorable‐risk mutations, such as <em>FLT3</em>‐ITD and <em>KMT2A</em>‐partial tandem duplication mutations. Conversely, when co‐occurring with favorable‐risk mutations like nucleophosmin <em>(NPM1</em>) and <em>CEBPA</em>, it seemed to further enhance the favorable effect of these mutations. A previous study from The University of Texas MD Anderson Cancer Center (MDACC) also demonstrated that the presence of an <em>FLT3</em>‐TKD co‐mutation was associated with improved relapse‐free survival and a trend toward improved OS in <em>NPM1</em>
<sup>mut</sup> AML.<a href="#cncr70032-bib-0011" class="usa-link" aria-describedby="cncr70032-bib-0011">
<sup>11</sup>
</a>
<em>FLT3‐</em>TKD and <em>NPM1</em> mutations often co‐occur, with prior studies reporting the presence of co‐occurring <em>NPM1</em> mutations in approximately 50%–55% of patients with <em>FLT3</em>‐TKD<sup>mut</sup>AML.<a href="#cncr70032-bib-0011" class="usa-link" aria-describedby="cncr70032-bib-0011">
<sup>11</sup>
</a>, <a href="#cncr70032-bib-0012" class="usa-link" aria-describedby="cncr70032-bib-0012">
<sup>12</sup>
</a> This emphasizes the importance of closely evaluating <em>NPM1</em> mutational status when assessing the prognostic and therapeutic implications of <em>FLT3</em>‐TKD<sup>mut</sup> AML.</p>
<p>In a more recent meta‐analysis of 10 studies, <em>FLT3</em>‐TKD mutation was not associated with a significant effect on disease‐free survival or OS.<a href="#cncr70032-bib-0013" class="usa-link" aria-describedby="cncr70032-bib-0013">
<sup>13</sup>
</a> However, that analysis did not evaluate co‐mutational status and its effect on prognosis. In addition, data regarding specific induction chemotherapy regimens were not reported. With the exception of two studies, all of the other studies included in that meta‐analysis were published before 2017 and thus were unlikely to capture the effect of subsequently approved treatments for frontline AML, including venetoclax (VEN) and FLT3i drugs.<a href="#cncr70032-bib-0014" class="usa-link" aria-describedby="cncr70032-bib-0014">
<sup>14</sup>
</a>, <a href="#cncr70032-bib-0015" class="usa-link" aria-describedby="cncr70032-bib-0015">
<sup>15</sup>
</a> There is very limited data in published literature describing the outcomes of frontline <em>FLT3</em>‐TKD<sup>mut</sup> AML incorporating these more recently approved and effective agents. In the current study, we describe the characteristics and outcomes of one of the largest cohorts of frontline <em>FLT3</em>‐TKD<sup>mut</sup> AML, including for the first time the effect of incorporating VEN, FLT3i drugs, and the role of allogeneic stem cell transplantation (ASCT) on outcomes in frontline <em>FLT3</em>‐TKD<sup>mut</sup> AML. We also describe the prognostic impact of <em>NPM1</em> co‐mutation in patients with <em>FLT3</em>‐TKD<sup>mut</sup> AML.</p></section><section id="cncr70032-sec-0020"><h2 class="pmc_sec_title">MATERIALS AND METHODS</h2>
<section id="cncr70032-sec-0030"><h3 class="pmc_sec_title">Study design and patient population</h3>
<p>This was a retrospective study conducted at MDACC. We initially screened 2922 adult patients with newly diagnosed AML (excluding those with acute promyelocytic leukemia and core binding factor AML) who received frontline therapy at MDACC from January 2012 to March 2024 (see Figure <a href="#cncr70032-fig-0001" class="usa-link">1</a>, Consolidated Standards of Reporting Trials [CONSORT] diagram). Among these, 124 patients had <em>FLT3</em>‐TKD<sup>mut</sup> AML, and 126 had <em>NPM1</em> mutations with <em>FLT3</em>‐TKD wild type (<em>FLT3</em>‐TKD<sup>wt</sup>) AML. <em>FLT3</em> mutations were detected using polymerase chain reaction analysis followed by capillary electrophoresis, as described previously.<a href="#cncr70032-bib-0016" class="usa-link" aria-describedby="cncr70032-bib-0016">
<sup>16</sup>
</a> Other mutations were detected with targeted next‐generation sequencing (NGS) performed at our institution (using panels with either 28, 53, or 81 myeloid genes, depending on the period when NGS was performed, as previously published by our group).<a href="#cncr70032-bib-0017" class="usa-link" aria-describedby="cncr70032-bib-0017">
<sup>17</sup>
</a>, <a href="#cncr70032-bib-0018" class="usa-link" aria-describedby="cncr70032-bib-0018">
<sup>18</sup>
</a> For the current study, we included patients in two cohorts: <em>FLT3</em>‐TKD<sup>mut</sup> AML (with or without <em>NPM1</em> mutation) and <em>NPM1</em>
<sup>mut</sup>/<em>FLT3</em>‐TKD<sup>wt</sup> AML (used as a <em>comparator</em> cohort to better assess the effect of co‐occurrence of <em>NPM1</em> and <em>FLT3</em>‐TKD mutations, which are relatively common, as described above<a href="#cncr70032-bib-0011" class="usa-link" aria-describedby="cncr70032-bib-0011">
<sup>11</sup>
</a>, <a href="#cncr70032-bib-0012" class="usa-link" aria-describedby="cncr70032-bib-0012">
<sup>12</sup>
</a>). Patients with <em>FLT3‐</em>ITD<sup>mut</sup> AML were excluded from both cohorts.</p>
<figure class="fig xbox font-sm" id="cncr70032-fig-0001"><h4 class="obj_head">FIGURE 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fa1/12335293/e527e6514057/CNCR-131-e70032-g003.jpg" loading="lazy" id="jats-graphic-1" height="482" width="709" alt="FIGURE 1"></p>
<div class="p text-right font-secondary"><a href="figure/cncr70032-fig-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>CONSORT diagram. +/− indicates with or without; AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; CBF, core binding factor; CONSORT, Consolidated Standards of Reporting Trials; FLT3, Fms‐like tyrosine kinase 3; ITD, internal tandem duplication; mut, mutated; NPM1, nucleophosmin; TKD, tyrosine kinase domain; wt, wild type. Created in BioRender (BioRender.com), no. SO28LIVY3D.</p></figcaption></figure><p>Based on age and fitness at the time of frontline treatment, patients received induction with either IC or low‐intensity therapy (LIT). IC treatment regimens included high‐dose cytarabine (1–2 g/m<sup>2</sup>) in combination with anthracyclines (idarubicin, daunorubicin) and/or nucleoside analogues (cladribine, fludarabine, clofarabine). LIT regimens included combined azacitidine, decitabine, and guadecitabine (HMA) either alone or in combination with VEN (since 2018). In addition, patients who were treated on protocol with the regimen of cladribine and low‐dose cytarabine (&lt;100 mg/m<sup>2</sup>) with or without VEN<a href="#cncr70032-bib-0019" class="usa-link" aria-describedby="cncr70032-bib-0019">
<sup>19</sup>
</a> and those who received targeted therapies, such as an FLT3i alone or in combination with HMA or HMA/VEN, were also included in the LIT group. Patients who were treated either on or off clinical trial protocols were included.</p></section><section id="cncr70032-sec-0040"><h3 class="pmc_sec_title">Study objectives</h3>
<p>The primary study objective was to describe the response rates and survival outcomes (OS and EFS) of patients with <em>FLT3</em>‐TKD<sup>mut</sup> AML according to the type of induction therapy received (IC or LIT). Response assessment was performed using the International Working Group criteria.<a href="#cncr70032-bib-0020" class="usa-link" aria-describedby="cncr70032-bib-0020">
<sup>20</sup>
</a> A composite complete remission (CRc) was defined as the sum of patients who had complete remission (CR) and patients who had complete remission with incomplete hematologic recovery (CRi). Secondary objectives included determining the prognostic effect of <em>NPM1</em> co‐mutation, VEN‐containing and/or FLT3i‐containing IC or LIT therapies, and ASCT in patients with <em>FLT3</em>‐TKD<sup>mut</sup> AML. We also evaluated the outcomes of <em>FLT3</em>‐TKD wild‐type status in patients with <em>NPM1</em>
<sup>mut</sup> AML.</p></section><section id="cncr70032-sec-0050"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p>Descriptive statistics were used to evaluate baseline imbalances between groups. The Fisher exact test and the two‐sided Mann–Whitney <em>U</em> test were used to assess differences in groups for categorical and continuous variables, respectively. The level of significance was set at α &lt; .05. Patients who died or were lost to follow‐up after induction and before response assessment were also classified as nonresponders. OS was calculated from the date of treatment initiation to the date of death or last follow‐up. EFS was calculated from the date of treatment initiation to date of the earliest event (start of alternate therapy for no response, relapse, or death, whichever occurred first) and was censored if the patient was alive and without any event at last follow‐up. Survival outcomes were estimated using the Kaplan–Meier method, and the log‐rank test was used to assess survival differences between groups. GraphPad Prism version 10.0 (GraphPad Inc.) and R studio version 4.4.2 (R Core Team) were used to perform statistical analyses.</p>
<section id="cncr70032-sec-0060"><h4 class="pmc_sec_title">Landmark analysis</h4>
<p>Landmark analysis was conducted to compare the OS of patients who underwent ASCT versus those who did not. Only patients who were aged 70 years or younger at the time of induction therapy, had achieved a CRc, and were alive at the specified landmark time were included in the comparator/nontransplantation group. The median time to ASCT for the population being evaluated was chosen as the landmark time for analysis. An age cutoff for the comparator/nontransplantation group was chosen based on the age of the oldest patient with <em>FLT3</em>‐TKD<sup>mut</sup> AML who underwent ASCT in our cohort, which was 70 years.</p></section></section></section><section id="cncr70032-sec-0070"><h2 class="pmc_sec_title">RESULTS</h2>
<p>In total, 250 patients were included in two cohorts: an <em>FLT3‐</em>TKD<sup>mut</sup> AML cohort (<em>n</em> = 124) and an <em>NPM1</em>
<sup>mut</sup>/<em>FLT3‐</em>TKD<sup>wt</sup> AML cohort (<em>n</em> = 126).</p>
<section id="cncr70032-sec-0080"><h3 class="pmc_sec_title">
<em>FLT3‐</em>TKD<sup>mut</sup> AML cohort</h3>
<p>In the entire <em>FLT3</em>‐TKD<sup>mut</sup> cohort (<em>n</em> = 124), the median age was 65 years (range, 25–89 years), and 55 patients (44%) were female. Baseline characteristics are summarized in Table <a href="#cncr70032-tbl-0001" class="usa-link">1</a>. The most common <em>FLT3</em>‐TKD mutation was D835 (78%), followed by N676 (11%), and D839 (4%). Details of all individual TKD point mutations included are provided in the Supporting Information (see Table <a href="#cncr70032-sup-0001" class="usa-link">S1</a>). Frontline induction therapy was IC in 54 patients (44%) and LIT in 70 patients (56%).</p>
<section class="tw xbox font-sm" id="cncr70032-tbl-0001"><h4 class="obj_head">TABLE 1.</h4>
<div class="caption p"><p>Baseline characteristics of patients in the <em>FLT3</em>‐tyrosine kinase domain–mutated cohort, <em>n</em> = 124.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<thead valign="bottom">
<tr>
<th align="left" valign="bottom" rowspan="1" colspan="1"></th>
<th align="left" valign="bottom" rowspan="1" colspan="1"></th>
<th style="border-bottom:solid 1px #000000" colspan="2" align="left" valign="bottom" rowspan="1">No. (%) or median [range]</th>
<th rowspan="4" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">
<em>p</em>
</th>
<th style="border-bottom:solid 1px #000000" colspan="2" align="left" valign="bottom" rowspan="1">No. (%) or median [range]</th>
<th rowspan="4" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">
<em>p</em>
</th>
</tr>
<tr>
<th align="left" valign="bottom" rowspan="1" colspan="1"></th>
<th rowspan="3" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">
<em>FLT3</em>‐TKD<sup>mut</sup> full cohort, <em>n</em> = 124</th>
<th rowspan="2" style="border-bottom:solid 1px #000000" colspan="2" align="left" valign="bottom">IC, <em>n</em> = 54</th>
<th rowspan="2" style="border-bottom:solid 1px #000000" colspan="2" align="left" valign="bottom">LIT, <em>n</em> = 70</th>
</tr>
<tr><th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">Parameters</th></tr>
<tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">
<em>NPM1</em>
<sup>mut</sup>, <em>n</em> = 24 (44%)</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">
<em>NPM1</em>
<sup>wt</sup>, <em>n</em> = 30 (56%)</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">
<em>NPM1</em>
<sup>mut</sup>, <em>n</em> = 31 (44%)</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">
<em>NPM1</em>
<sup>wt</sup>, <em>n</em> = 39 (56%)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Age, years</td>
<td align="left" valign="top" rowspan="1" colspan="1">65 [25–89]</td>
<td align="left" valign="top" rowspan="1" colspan="1">54 [28‐63]</td>
<td align="left" valign="top" rowspan="1" colspan="1">54 [25–80]</td>
<td align="center" valign="top" rowspan="1" colspan="1">.9</td>
<td align="left" valign="top" rowspan="1" colspan="1">71 [60–89]</td>
<td align="left" valign="top" rowspan="1" colspan="1">70 [50–87]</td>
<td align="center" valign="top" rowspan="1" colspan="1">.7</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">≥60 years</td>
<td align="left" valign="top" rowspan="1" colspan="1">82 (66.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">5 (21.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">9 (30.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">.5</td>
<td align="left" valign="top" rowspan="1" colspan="1">31 (100.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">37 (95.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">.5</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Females</td>
<td align="left" valign="top" rowspan="1" colspan="1">55 (44.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">11 (46.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">13 (43.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
<td align="left" valign="top" rowspan="1" colspan="1">13 (42.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">18 (46.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">.8</td>
</tr>
<tr><td colspan="8" align="left" valign="top" rowspan="1">Baseline peripheral blood counts</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">WBC, ×10<sup>9</sup>/L</td>
<td align="left" valign="top" rowspan="1" colspan="1">4.9 [0.1−184.0]</td>
<td align="left" valign="top" rowspan="1" colspan="1">7.8 [1.4–69.8]</td>
<td align="left" valign="top" rowspan="1" colspan="1">5.6 [0.6–184.0]</td>
<td align="center" valign="top" rowspan="1" colspan="1">.8</td>
<td align="left" valign="top" rowspan="1" colspan="1">2.7 [0.4–114.0]</td>
<td align="left" valign="top" rowspan="1" colspan="1">5.85 [0.1–46.1]</td>
<td align="center" valign="top" rowspan="1" colspan="1">.7</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hb, g/dL</td>
<td align="left" valign="top" rowspan="1" colspan="1">8.7 [6.8−12.1]</td>
<td align="left" valign="top" rowspan="1" colspan="1">9.1 [7.1–11.2]</td>
<td align="left" valign="top" rowspan="1" colspan="1">8.6 [6.8–11.6]</td>
<td align="center" valign="top" rowspan="1" colspan="1">.5</td>
<td align="left" valign="top" rowspan="1" colspan="1">8.8 [6.8–11.2]</td>
<td align="left" valign="top" rowspan="1" colspan="1">8.7 [7.1–12.1]</td>
<td align="center" valign="top" rowspan="1" colspan="1">.8</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Platelets, ×10<sup>9</sup>/L</td>
<td align="left" valign="top" rowspan="1" colspan="1">29.0 [6.0−350.0]</td>
<td align="left" valign="top" rowspan="1" colspan="1">26.5 [12.0–77.0]</td>
<td align="left" valign="top" rowspan="1" colspan="1">29.0 [21.0–94.0]</td>
<td align="center" valign="top" rowspan="1" colspan="1">.6</td>
<td align="left" valign="top" rowspan="1" colspan="1">31.0 [6.0–160.0]</td>
<td align="left" valign="top" rowspan="1" colspan="1">29.0 [6.0–350.0]</td>
<td align="center" valign="top" rowspan="1" colspan="1">.8</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Baseline bone marrow blasts, %</td>
<td align="left" valign="top" rowspan="1" colspan="1">60.0 [12.0−94.0]</td>
<td align="left" valign="top" rowspan="1" colspan="1">70.0 [16.0–92.0]</td>
<td align="left" valign="top" rowspan="1" colspan="1">60.0 [21.0–94.0]</td>
<td align="center" valign="top" rowspan="1" colspan="1">.9</td>
<td align="left" valign="top" rowspan="1" colspan="1">56.0 [21.0–91.0]</td>
<td align="left" valign="top" rowspan="1" colspan="1">57.0 [12.0–92.0]</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Secondary AML</td>
<td align="left" valign="top" rowspan="1" colspan="1">32 (26.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">6 (20.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">.03<a href="#cncr70032-note-0004" class="usa-link">
<sup>a</sup>
</a>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">5 (16.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">21 (54.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">.001<a href="#cncr70032-note-0004" class="usa-link">
<sup>a</sup>
</a>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Cytogenetics</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td colspan="2" align="left" valign="top" rowspan="1"></td>
<td rowspan="6" align="center" valign="top" colspan="1">.02<a href="#cncr70032-note-0004" class="usa-link">
<sup>a</sup>
</a>
</td>
<td colspan="2" align="left" valign="top" rowspan="1"></td>
<td rowspan="6" align="center" valign="top" colspan="1">.01<a href="#cncr70032-note-0004" class="usa-link">
<sup>a</sup>
</a>
</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Diploid</td>
<td align="left" valign="top" rowspan="1" colspan="1">61 (49.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">20 (83)</td>
<td align="left" valign="top" rowspan="1" colspan="1">12 (40.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">19 (61.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">10 (26)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Complex</td>
<td align="left" valign="top" rowspan="1" colspan="1">18 (15.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">1 (4.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">5 (17.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">3 (10.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">9 (23)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Isolated −5/5q− or −7/7q−</td>
<td align="left" valign="top" rowspan="1" colspan="1">6 (5.0.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">3 (10.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">3 (8.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">11q23 rearrangement</td>
<td align="left" valign="top" rowspan="1" colspan="1">6 (5.0.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">1 (3.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">5 (13.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Others</td>
<td align="left" valign="top" rowspan="1" colspan="1">33 (27.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">3 (13.0)<a href="#cncr70032-note-0005" class="usa-link">
<sup>b</sup>
</a>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">9 (30.0)<a href="#cncr70032-note-0006" class="usa-link">
<sup>c</sup>
</a>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">9 (29.0)<a href="#cncr70032-note-0007" class="usa-link">
<sup>d</sup>
</a>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">12 (31.0)<a href="#cncr70032-note-0008" class="usa-link">
<sup>e</sup>
</a>
</td>
</tr>
<tr><td colspan="8" align="left" valign="top" rowspan="1">Mutations, no./total no (%)</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<em>ASXL1</em>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">17/79 (22.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0/15 (0.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">5/23 (22.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">.14</td>
<td align="left" valign="top" rowspan="1" colspan="1">1/19 (5.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">11/22 (50.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">.002<a href="#cncr70032-note-0004" class="usa-link">
<sup>a</sup>
</a>
</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<em>DNMT3A</em>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">34/91 (37.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">10/20 (50.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">3/21 (14.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">.02<a href="#cncr70032-note-0005" class="usa-link">
<sup>a</sup>
</a>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">14/26 (54.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">7/24 (29.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">.09</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<em>IDH1</em>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">15/77 (20.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">3/16 (19.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0/20 (0.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">.08</td>
<td align="left" valign="top" rowspan="1" colspan="1">8/22 (36.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">4/19 (21.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">.32</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<em>IDH2</em>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">16/78 (21.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">3/15 (20.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">4/21 (19.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
<td align="left" valign="top" rowspan="1" colspan="1">6/22 (27.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">3/20 (15.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">.46</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<em>RAS</em> pathway</td>
<td align="left" valign="top" rowspan="1" colspan="1">41/92 (45.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">8/19 (42.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">10/22 (46.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
<td align="left" valign="top" rowspan="1" colspan="1">8/22 (36.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">15/29 (52.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">.39</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<em>RUNX1</em>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">14/85 (17.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0/12 (0.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">4/19 (21.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">.14</td>
<td align="left" valign="top" rowspan="1" colspan="1">0/18 (0.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">10/36 (39.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">.03<a href="#cncr70032-note-0005" class="usa-link">
<sup>a</sup>
</a>
</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<em>TET2</em>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">17/88 (19.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">2/16 (13.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">2/22 (9.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
<td align="left" valign="top" rowspan="1" colspan="1">6/25 (24.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">7/25 (28.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<em>TP53</em>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">8/77 (10.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0/15 (0.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">1/19 (5.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
<td align="left" valign="top" rowspan="1" colspan="1">0/18 (0.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">7/25 (28.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">.01<a href="#cncr70032-note-0005" class="usa-link">
<sup>a</sup>
</a>
</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<em>WT1</em>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">8/71 (11.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">1/13 (8.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">5/20 (25.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">.36</td>
<td align="left" valign="top" rowspan="1" colspan="1">1/18 (6.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">1/20 (5.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">ELN 2022 risk stratification</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="center" valign="top" rowspan="1" colspan="1">&lt; .0001<a href="#cncr70032-note-0005" class="usa-link">
<sup>a</sup>
</a>
</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="center" valign="top" rowspan="1" colspan="1">&lt; .0001<a href="#cncr70032-note-0005" class="usa-link">
<sup>a</sup>
</a>
</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Favorable</td>
<td align="left" valign="top" rowspan="1" colspan="1">51 (41.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">23 (96.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1">28 (90.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Intermediate</td>
<td align="left" valign="top" rowspan="1" colspan="1">14 (11.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">12 (40.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">2 (5.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Adverse</td>
<td align="left" valign="top" rowspan="1" colspan="1">59 (48.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">1 (4.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">18 (60.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1">3 (10.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">37 (95.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr><td colspan="8" align="left" valign="top" rowspan="1">Addition of VEN and/or FLT3i</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">VEN only</td>
<td align="left" valign="top" rowspan="1" colspan="1">44 (36.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">9 (38.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">8 (27.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">.6</td>
<td align="left" valign="top" rowspan="1" colspan="1">14 (45.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">13 (33.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">.3</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">FLT3i only</td>
<td align="left" valign="top" rowspan="1" colspan="1">14 (11.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">3 (13.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">7 (23.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">.5</td>
<td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">4 (10.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">.1</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Both VEN and FLT3i</td>
<td align="left" valign="top" rowspan="1" colspan="1">13 (11.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
<td align="left" valign="top" rowspan="1" colspan="1">3 (10.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">10 (26.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">.1</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Neither VEN nor FLT3i</td>
<td align="left" valign="top" rowspan="1" colspan="1">53 (43.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">12 (50.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">15 (50.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.0</td>
<td align="left" valign="top" rowspan="1" colspan="1">14 (45.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">12 (31.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">.3</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/cncr70032-tbl-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="cncr70032-note-0003"><p>Abbreviations: AML, acute myeloid leukemia; ELN, European LeukemiaNet; Hb, hemoglobin; FLT3, Fms‐like tyrosine kinase 3; FLT3i, Fms‐like tyrosine kinase 3 inhibitor; IC, intensive chemotherapy; LIT, lower intensity therapy; mut, mutated; NPM1, nucleophosmin; VEN, venetoclax; WBC, white blood cells; wt, wild type.</p></div>
<div class="fn" id="cncr70032-note-0004">
<sup>
<sup>a</sup>
</sup><p class="display-inline">These <em>p</em> values indicate a statistically significant difference.</p>
</div>
<div class="fn" id="cncr70032-note-0005">
<sup>
<sup>b</sup>
</sup><p class="display-inline">Included +8, −Y, and del(4q).</p>
</div>
<div class="fn" id="cncr70032-note-0006">
<sup>
<sup>c</sup>
</sup><p class="display-inline">Included +8, +9, +11, −12, del(12p), i(8q), and der(3)t(3;8).</p>
</div>
<div class="fn" id="cncr70032-note-0007">
<sup>
<sup>d</sup>
</sup><p class="display-inline">Included +4, +8, −Y, t(1:22), inv(9), and del(9q).</p>
</div>
<div class="fn" id="cncr70032-note-0008">
<sup>
<sup>e</sup>
</sup><p class="display-inline">Included +1, +8, +11, +13, +19, + 21, −10, i(17q), and del(12p).</p>
</div>
</div></section><section id="cncr70032-sec-0090"><h4 class="pmc_sec_title">Outcomes of patients with FLT3‐TKD<sup>mut</sup> AML receiving frontline intensive chemotherapy</h4>
<p>In the IC <em>FLT3</em>‐TKD<sup>mut</sup> cohort (<em>n</em> = 54), the median age was 54 years (range, 25–80 years). <em>NPM1</em> was co‐mutated in 24 patients (44%). VEN was added to the IC regimen in 17 patients (32%), an FLT3i was added in 10 patients (18%), and neither was added in 27 patients (50%). Details of the FLT3i drugs added and the specific regimens used are provided in Figure <a href="#cncr70032-fig-0002" class="usa-link">2</a>. In the IC cohort, in total, 44 patients (81%) attained a CRc (for response details, see Figure <a href="#cncr70032-fig-0002" class="usa-link">2A</a>). At a median follow‐up of 43 months (95% confidence interval [CI], 30.6–50.6 months), the median OS for the IC <em>FLT3</em>‐TKD<sup>mut</sup> cohort (<em>n</em> = 54) was not reached (NR; 95% CI, 12.5 months to NR), the 3‐year OS rate was 56%. The median event‐free survival (EFS) was also NR (95% CI, 10 months to NR), and 3‐year EFS rate was 53% (Figure <a href="#cncr70032-fig-0003" class="usa-link">3A,B</a>).</p>
<figure class="fig xbox font-sm" id="cncr70032-fig-0002"><h5 class="obj_head">FIGURE 2.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fa1/12335293/05371c8ff5e7/CNCR-131-e70032-g001.jpg" loading="lazy" id="jats-graphic-3" height="843" width="709" alt="FIGURE 2"></p>
<div class="p text-right font-secondary"><a href="figure/cncr70032-fig-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Response rates in the IC <em>FLT3‐</em>TKD<sup>mut</sup> cohort. CR indicates complete remission; CRc, composite complete remission; CRi, complete remission with incomplete hematologic recovery; FLT3, Fms‐like tyrosine kinase 3; IC, intensive chemotherapy; mut, mutated; NPM1, nucleophosmin; NR, not reached; TKD, tyrosine kinase domain; wt, wild type.</p></figcaption></figure><figure class="fig xbox font-sm" id="cncr70032-fig-0003"><h5 class="obj_head">FIGURE 3.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fa1/12335293/4283e5321bb9/CNCR-131-e70032-g004.jpg" loading="lazy" id="jats-graphic-5" height="500" width="709" alt="FIGURE 3"></p>
<div class="p text-right font-secondary"><a href="figure/cncr70032-fig-0003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Survival outcomes in the IC <em>FLT3‐</em>TKD<sup>mut</sup> cohort. IC indicates intensive chemotherapy; EFS, event‐free survival; FLT2, Fms‐like tyrosine kinase 3; mF/U, median follow‐up; mOS, median overall survival; mos, months; mut, mutated; NAR, number at risk; NPM1, nucleophosmin; OS, overall survival; TKD, tyrosine kinase domain; wt, wild type.</p></figcaption></figure><p>When stratified by the addition of VEN and/or an FLT3i, a CRc was attained in 16 of 17 patients (94%) who received VEN, seven of 10 (70%) who received an FLT3i, and 21 of 27 (78%) who received neither VEN nor an FLT3i (Figure <a href="#cncr70032-fig-0002" class="usa-link">2B</a>). The 3‐year OS rate for IC + VEN, IC + FLT3i, and IC alone was 74%, 70%, and 42%, respectively (<em>p</em> = .1); whereas the 3‐year EFS rate for these groups was 74%, 70%, and 35%, respectively (<em>p</em> = .05). Pair‐wise log‐rank tests indicated improved EFS (<em>p</em> = .03) and a trend toward improved OS (<em>p</em> = .07) with IC + VEN versus IC alone. In addition, there was a trend toward improved EFS and OS (<em>p</em> = .2 for both) with IC + FLT3i versus IC alone (see Figure <a href="#cncr70032-sup-0001" class="usa-link">S1</a>). There was no difference in OS or EFS with IC + VEN versus IC + FLT3i (<em>p</em> = .7 and <em>p</em> = .6. respectively).</p>
<p>When stratifying the IC <em>FLT3</em>‐TKD<sup>mut</sup> cohort according to <em>NPM1</em> status, the <em>NPM1</em>
<sup>wt</sup> group had more patients with secondary AML and adverse cytogenetics (including complex, chromosome 5 and 7 deletion, and other abnormalities; Table <a href="#cncr70032-tbl-0001" class="usa-link">1</a>). A CRc was attained in 24 of 24 <em>NPM1</em>–co‐mutated patients (100%) and in 20 of 30 <em>NPM1</em>
<sup>wt</sup> patients (67%; for response details, see Figure <a href="#cncr70032-fig-0002" class="usa-link">2A</a>). In addition, <em>NPM1</em>–co‐mutated patients a had higher median OS and median EFS compared with <em>NPM1</em>
<sup>wt</sup> patients: the median OS was NR for both OS and EFS (3‐year OS, 74% vs. 40%, respectively; hazard ratio [HR], 0.4; 95% CI, 0.2–0.9; <em>p</em> = .03) and the median EFS was NR for both (3‐year EFS, 65% vs. 42%, respectively; HR, 0.4; 95% CI, 0.2–0.96; <em>p</em> = .046; see Figure <a href="#cncr70032-fig-0003" class="usa-link">S3C,D</a>).</p>
<p>Among patients in the IC <em>FLT3</em>‐TKD<sup>mut</sup> AML cohort (<em>n</em> = 54), 25 patients (46%) underwent ASCT in first remission, with median time to ASCT (from the date of treatment initiation) of 4.4 months (range, 2.1–14.2 months). For these patients, the median age was 47 years (range, 25–63 years), and 13 patients (52%) had <em>NPM1</em> co‐mutations. On landmark analysis, which was set at 4.4 months, patients who underwent ASCT had numerically higher but statistically nonsignificantly longer 3‐year OS compared with those who did not undergo ASCT (median OS, NR for both; 3‐year OS, 83% vs. 64%, respectively; HR, 0.4; 95% CI, 0.1–1.4; <em>p</em> = .1; Figure <a href="#cncr70032-sup-0001" class="usa-link">S2</a>A). When stratified by <em>NPM1</em> status, OS was similar with and without ASCT among <em>NPM1</em>–co‐mutated patients (3‐year OS, 77% vs. 70%, respectively; <em>p</em> = .4). Conversely, among patients without <em>NPM1</em> co‐mutations, those who underwent ASCT had a longer median OS compared with those who did not, albeit with small numbers in this comparison (median OS, NR for both; 3‐year OS, 89% vs. 30%, respectively; HR, 0.1; 95% CI, 0.01–1.1; <em>p</em> = .02; see Figure <a href="#cncr70032-sup-0001" class="usa-link">S2B,C</a>).</p></section><section id="cncr70032-sec-0100"><h4 class="pmc_sec_title">Outcomes of patients with FLT3‐TKD<sup>mut</sup> AML receiving frontline induction with low intensity therapy</h4>
<p>In the LIT <em>FLT3</em>‐TKD<sup>mut</sup> cohort (<em>n</em> = 70), the median age was 70.5 years (range, 50–89 years). <em>NPM1</em> was co‐mutated in 31 patients (44%). VEN was added to the LIT regimen in 27 patients (39%), an FLT3i was added in four patients (6%), both an FLT3i and VEN were added (triplet regimen) in 13 patients (19%), and neither was added in 26 patients (37%). Details of the FLT3i drugs added and the specific regimens used are provided in Figure <a href="#cncr70032-fig-0004" class="usa-link">4</a>. In total, 44 of 70 patients (63%) attained a CRc (for response details, see Figure <a href="#cncr70032-fig-0004" class="usa-link">4A</a>). After a median follow‐up of 40 months (95% CI, 27.3–53.2 months), the median OS for the full LIT <em>FLT3</em>‐TKD<sup>mut</sup> cohort (<em>n</em> = 70) was 10.9 months (95% CI, 5.5–16.1 months), and the median EFS was 4.7 months (95% CI, 2.6–8.8 months; Figure <a href="#cncr70032-fig-0005" class="usa-link">5A,B</a>).</p>
<figure class="fig xbox font-sm" id="cncr70032-fig-0004"><h5 class="obj_head">FIGURE 4.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fa1/12335293/059f282893cd/CNCR-131-e70032-g005.jpg" loading="lazy" id="jats-graphic-7" height="846" width="709" alt="FIGURE 4"></p>
<div class="p text-right font-secondary"><a href="figure/cncr70032-fig-0004/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Response rates in the LIT <em>FLT3‐</em>TKD<sup>mut</sup> cohort. CR indicates complete remission; CRc, composite complete remission; CRi, complete remission with incomplete hematologic recovery; FLT3, Fms‐like tyrosine kinase 3; LIT, lower intensity therapy; MLFS, morphologic leukemic‐free state; mut, mutated; NPM1, nucleophosmin; NR, not reached; TKD, tyrosine kinase domain; wt, wild type.</p></figcaption></figure><figure class="fig xbox font-sm" id="cncr70032-fig-0005"><h5 class="obj_head">FIGURE 5.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fa1/12335293/78fe72110e9a/CNCR-131-e70032-g002.jpg" loading="lazy" id="jats-graphic-9" height="500" width="709" alt="FIGURE 5"></p>
<div class="p text-right font-secondary"><a href="figure/cncr70032-fig-0005/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Survival outcomes in the LIT <em>FLT3‐</em>TKD<sup>mut</sup> cohort. EFS indicates event‐free survival; FLT3, Fms‐like tyrosine kinase 3; LIT, lower intensity therapy; mEFS, median event‐free survival; mF/U, median follow‐up; mOS, median overall survival; mos, months; mut, mutated; NAR, number at risk; NPM1, nucleophosmin; OS, overall survival; TKD, tyrosine kinase domain; wt, wild type; yr, year.</p></figcaption></figure><p>When stratified according to the addition of VEN and/or an FLT3i, a CRc was attained in 21 of 27 patients (78%) who received LIT + VEN, in zero of four (0%) who received LIT + FLT3i, in 11 of 13 (85%) who received LIT + VEN + FLT3i, and in 12 of 26 (46%) who received neither (Figure <a href="#cncr70032-fig-0004" class="usa-link">4B</a>). The median OS for patients who received LIT + VEN, LIT + FLT3i, LIT + VEN + FLT3i, and LIT alone was 16.2, 5.85, 16.6, and 6.4 months, respectively (<em>p</em> = .1); whereas the median EFS for these groups was 5.6, 1.9, 10.4, and 4.2 months, respectively (<em>p</em> = .02).</p>
<p>When stratifying the LIT <em>FLT3</em>‐TKD<sup>mut</sup> cohort by <em>NPM1</em> status, the LIT <em>NPM1</em>
<sup>wt</sup> group had fewer patients with diploid karyotype, and more patients with secondary AML and adverse‐risk mutations, including <em>TP53, ASXL1</em>, and <em>RUNX1</em> (Table <a href="#cncr70032-tbl-0001" class="usa-link">1</a>). A CRc was attained in 23 of 31 <em>NPM1</em>
<sup>mut</sup> patients (74%) and in 21 of 39 <em>NPM1</em>
<sup>wt</sup> patients (54%; Figure <a href="#cncr70032-fig-0004" class="usa-link">4A</a>). In addition, <em>NPM1</em>
<sup>
<em>mut</em>
</sup> patients had a longer median OS compared with <em>NPM1</em>
<sup>
<em>wt</em>
</sup> patients (median OS, 16.6 months [95% CI, 8.7–35 months] vs. 6.0 months [95% CI, 2.6–14 months], respectively; HR, 0.6; 95% CI, 0.32–0.98; <em>p</em> = .04) and trend toward a longer median EFS (10.4 months [95% CI, 4.2–17 months] vs. 2.7 months [95% CI, 1.8–5.3 months]; HR, 0.6; 95% CI, 0.35–1.01; <em>p</em> = .05; Figure <a href="#cncr70032-fig-0005" class="usa-link">5C,D</a>).</p>
<p>Of the entire LIT <em>FLT3</em>‐TKD<sup>mut</sup> group (<em>n</em> = 70), in total, only 10 patients (14%) underwent ASCT in first remission, in line with expectations for this older population, with median time to stem cell transplantation of 3.8 months (range, 2.7–5.5 months). For these patients, the median age was 65.5 years (range, 50–70 years), with <em>NPM1</em> co‐mutation in five patients (50%). On landmark analysis set at 3.8 months, there was no significant difference in median OS among patients who received ASCT compared with those who did not (median OS, NR [95% CI, 6.4 months to NR] vs. 35 months [95% CI, 14 months to NR], respectively; HR, 0.4; 95% CI, 0.1–1.5; <em>p</em> = .2; see Figure <a href="#cncr70032-sup-0001" class="usa-link">S3A</a>). On stratifying by <em>NPM1</em> status, no OS benefit was noted with ASCT among <em>NPM1</em>–co‐mutated patients. However, <em>NPM1</em>
<sup>wt</sup> patients who underwent ASCT had a trend toward longer median OS compared to those who did not undergo ASCT (median OS, NR [95% CI, 17 months to NR] vs. 15.1 months [95% CI, 4.4 months to NR], respectively; HR, 0.2; 95% CI, 0.03–1.5; <em>p</em> = .1; see Figure <a href="#cncr70032-sup-0001" class="usa-link">S3B,C</a>).</p></section><section id="cncr70032-sec-0110"><h4 class="pmc_sec_title">Use of VEN and/or FLT3i stratified by time period of frontline treatment in the FLT3‐TKD<sup>mut</sup> AML cohort</h4>
<p>Patients in the <em>FLT3</em>‐TKD<sup>mut</sup> AML cohort (<em>n</em> = 124) received frontline treatment from July 2012 to October 2023. Among these, 43 patients (35%) received frontline treatment from 2012 to 2016, and the remaining 81 patients (65%) were treated from 2017 to 2023 (see Table <a href="#cncr70032-sup-0001" class="usa-link">S2</a>). In the 2012–2016 group, only five patients (12%) received either VEN or an FLT3i in combination with IC/LIT (all on clinical trial protocols). In contrast, 66 patients (82%) treated from 2017 to 2023 received either VEN and/or an FLT3i. This discrepancy likely reflects the greater use of VEN/FLT3i in frontline clinical trials during the latter time period as well as the subsequent regulatory approval of frontline FLT3i drugs for younger/fit patients with AML and VEN for older/unfit patients with AML.</p></section></section><section id="cncr70032-sec-0120"><h3 class="pmc_sec_title">
<em>NPM1</em>
<sup>mut</sup>/<em>FLT3‐</em>TKD<sup>wt</sup> AML cohort</h3>
<p>In the entire <em>NPM1</em>
<sup>mut</sup>/<em>FLT3</em>‐TKD<sup>wt</sup> cohort (<em>n</em> = 126), the median age was 67 years (range, 17–87 years), and 64 patients (51%) were female. Baseline characteristics are described in Table <a href="#cncr70032-tbl-0002" class="usa-link">2</a>. Frontline induction therapy was IC in 46 patients (37%) and LIT in 80 patients (63%).</p>
<section class="tw xbox font-sm" id="cncr70032-tbl-0002"><h4 class="obj_head">TABLE 2.</h4>
<div class="caption p"><p>Baseline characteristics of patients in the <em>NPM1</em>‐mutated/<em>FLT3‐</em>tyrosine kinase domain wild‐type cohort (<em>n</em> = 126).</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<thead valign="bottom">
<tr>
<th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">Parameters</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">No. (%) or median [range]</th>
<th style="border-bottom:solid 1px #000000" colspan="2" align="left" valign="bottom" rowspan="1">No. (%) or median [range]</th>
</tr>
<tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">
<em>NPM1</em>
<sup>mut</sup>/<em>FLT3</em>‐TKD<sup>wt</sup> full cohort, <em>n</em> = 126</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">IC, <em>n</em> = 46</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">LIT, <em>n</em> = 80</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Age, years</td>
<td align="left" valign="top" rowspan="1" colspan="1">67 [17–87]</td>
<td align="left" valign="top" rowspan="1" colspan="1">54 [17–74]</td>
<td align="left" valign="top" rowspan="1" colspan="1">72 [60–87]</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">≥60 years</td>
<td align="left" valign="top" rowspan="1" colspan="1">92 (73.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">12 (26.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">80 (100.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Females</td>
<td align="left" valign="top" rowspan="1" colspan="1">64 (51.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">32 (70.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">32 (40.0)</td>
</tr>
<tr><td colspan="4" align="left" valign="top" rowspan="1">Baseline peripheral blood counts</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">WBC, ×10<sup>9</sup>/L</td>
<td align="left" valign="top" rowspan="1" colspan="1">5.1 [0.2–127.4]</td>
<td align="left" valign="top" rowspan="1" colspan="1">6.5 [0.5–127.4]</td>
<td align="left" valign="top" rowspan="1" colspan="1">4.4 [0.2–64.3]</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hb, g/dL</td>
<td align="left" valign="top" rowspan="1" colspan="1">9.2 [7.1–12.5</td>
<td align="left" valign="top" rowspan="1" colspan="1">9.2 [7.1–11.7]</td>
<td align="left" valign="top" rowspan="1" colspan="1">9.3 [7.4–12.5]</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Platelets, ×10<sup>9</sup>/L</td>
<td align="left" valign="top" rowspan="1" colspan="1">40 [3–535]</td>
<td align="left" valign="top" rowspan="1" colspan="1">43 [6–431]</td>
<td align="left" valign="top" rowspan="1" colspan="1">33.5 [3.0–535.0]</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Baseline bone marrow blasts, %</td>
<td align="left" valign="top" rowspan="1" colspan="1">50.0 [5.0–95.0]</td>
<td align="left" valign="top" rowspan="1" colspan="1">53.0 [16.0–93.0]</td>
<td align="left" valign="top" rowspan="1" colspan="1">43.0 [5.0–95.0]</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Secondary AML</td>
<td align="left" valign="top" rowspan="1" colspan="1">18 (14.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">4 (9.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">14 (18.0)</td>
</tr>
<tr><td colspan="4" align="left" valign="top" rowspan="1">Cytogenetics</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Diploid</td>
<td align="left" valign="top" rowspan="1" colspan="1">80 (63.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">28 (61.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">52 (65.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Complex</td>
<td align="left" valign="top" rowspan="1" colspan="1">6 (5.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">2 (4.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">4 (5.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Isolated −5/5q− or −7/7q−</td>
<td align="left" valign="top" rowspan="1" colspan="1">2 (2.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">1 (2.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">1 (1.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Others</td>
<td align="left" valign="top" rowspan="1" colspan="1">38 (30.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">15 (33.0)<a href="#cncr70032-note-0010" class="usa-link">
<sup>a</sup>
</a>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">23 (29.0)<a href="#cncr70032-note-0011" class="usa-link">
<sup>b</sup>
</a>
</td>
</tr>
<tr><td colspan="4" align="left" valign="top" rowspan="1">Mutations, no./total no (%)</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<em>ASXL1</em>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">4/101 (4.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0/34 (0.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">4/67 (6.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<em>DNMT3A</em>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">44/119 (37.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">19/41 (46.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">25/78 (32.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<em>IDH1</em>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">20/125 (16.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">4/45 (9.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">16 (20.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<em>IDH2</em>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">27/125 (22.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">10/45 (22.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">17 (21.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<em>RAS</em>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">38/125 (30.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">15/45 (33.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">23 (29.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<em>RUNX1</em>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">1/99 (1.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0/35 (0.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">1/64 (2.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<em>TET2</em>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">20/98 (20.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">5/34 (15.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">15/64 (23.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<em>TP53</em>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">5/113 (4.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">2/39 (5.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">3/74 (4.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<em>WT1</em>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">7/95 (7.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">3/35 (9.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">4/60 (7.0)</td>
</tr>
<tr><td colspan="4" align="left" valign="top" rowspan="1">ELN 2022 risk stratification</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Favorable</td>
<td align="left" valign="top" rowspan="1" colspan="1">116 (92.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">41 (89.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">75 (94.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Intermediate</td>
<td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Adverse</td>
<td align="left" valign="top" rowspan="1" colspan="1">10 (8.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">5 (11.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">5 (6.0)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/cncr70032-tbl-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="cncr70032-note-0009"><p>Abbreviations: AML, acute myeloid leukemia; ELN, European LeukemiaNet; Hb, hemoglobin; FLT3, Fms‐like tyrosine kinase 3; IC, intensive chemotherapy; LIT, lower intensity therapy; mut, mutated; NPM1, nucleophosmin; WBC, white blood cells; wt, wild type.</p></div>
<div class="fn" id="cncr70032-note-0010">
<sup>
<sup>a</sup>
</sup><p class="display-inline">Included +4, +8, +19, +X, −22, t(9;22), t(3;9), del(9q), del(16q), and dup(17q).</p>
</div>
<div class="fn" id="cncr70032-note-0011">
<sup>
<sup>b</sup>
</sup><p class="display-inline">Included +8, +19, +21, +Y, +mar(4), −Y, t(3;10), del(9q), del(13q), del(20q), and +i(4q).</p>
</div>
</div></section><section id="cncr70032-sec-0130"><h4 class="pmc_sec_title">Outcomes of patients with <em>NPM1</em>
<sup>mut</sup>/<em>FLT3</em>‐TKD<sup>wt</sup> AML receiving frontline intensive chemotherapy</h4>
<p>In the IC <em>NPM1</em>
<sup>mut</sup>/<em>FLT3</em>‐TKD<sup>wt</sup> AML group (<em>n</em> = 46), the median age was 54 years (range, 17–74 years). VEN was added to IC in six patients (13%), and a CRc was attained in five of those six patients. IC alone was received by 40 patients (87%), and a CRc was achieved in 37 of those 40 patients (93%, all had a CR; see Figure <a href="#cncr70032-sup-0001" class="usa-link">S4</a>).</p>
<p>With a median follow‐up of 72 months (95% CI, 47.6–98.6 months), the median OS for the IC <em>NPM1</em>
<sup>mut</sup>/<em>FLT3</em>‐TKD<sup>wt</sup> cohort (<em>n</em> = 46) was 77.4 months (95% CI, 20.1 months to NR; 3‐year OS, 60%), and the median EFS was 39.5 months (95% CI, 12.4 months to NR; see Figure <a href="#cncr70032-sup-0001" class="usa-link">S5B,C</a>). On stratifying by the type of induction therapy received, there was no significant difference in OS between patients who received IC + VEN versus IC alone (median OS, NR [95% CI, 1.3 months to NR] vs. 39.6 months [95% CI, 19 months to NR], respectively; HR, 0.3; 95% CI, 0.09–1.00; 3‐year OS, 83% vs. 57%; <em>p</em> = .2; see Figure <a href="#cncr70032-sup-0001" class="usa-link">S5A</a>).</p>
<p>For the entire IC <em>NPM1</em>
<sup>mut</sup>/<em>FLT3</em>‐TKD<sup>wt</sup> AML cohort (<em>n</em> = 46), 19 patients (41%) underwent ASCT in first remission, and the median time to ASCT was 4.9 months (range, 1.9–9.2 months). For these patients, the median age was 54 years (range, 19–68 years). On landmark analysis, there was no OS benefit noted with ASCT (3‐year OS, 63% vs. 68% without ASCT; <em>p</em> = .8).</p>
<p>On comparing this <em>NPM1</em>
<sup>mut</sup>/<em>FLT3</em>‐TKD<sup>wt</sup> cohort with our prior <em>NPM1</em>
<sup>mut</sup>/<em>FLT3</em>‐TKD<sup>mut</sup> cohort (<em>n</em> = 24; as mentioned above) who received IC, there was no statistically significant difference in OS (3‐year OS, 60% vs. 74%, respectively) or EFS (log‐rank <em>p</em> = .2 for both; see <a href="#cncr70032-sup-0001" class="usa-link">Figure S5B,C</a>).</p></section><section id="cncr70032-sec-0140"><h4 class="pmc_sec_title">Outcomes of patients with <em>NPM1</em>
<sup>mut</sup>/<em>FLT3</em>‐TKD<sup>wt</sup> AML receiving frontline low‐intensity therapy</h4>
<p>In the LIT <em>NPM1</em>
<sup>mut</sup>/<em>FLT3</em>‐TKD<sup>wt</sup> cohort (<em>n</em> = 80), the median age was 72 years (range, 60–87 years). VEN was added to an LIT induction regimen in 34 patients (43%), with a CRc attained in 32 (94%). LIT alone was received by 46 patients (57%), with a CRc attained in 30 patients (65%; see Figure <a href="#cncr70032-sup-0001" class="usa-link">S6</a>).</p>
<p>With a median follow‐up of 70 months (95% CI, 52.3–82.4 months), the median OS was 14.9 months (95% CI, 10.6–32.6 months; 3‐year OS, 40%), and the median EFS was 12.1 months (95% CI, 7.7–19.9 months; 3‐year EFS, 33%; see Figure <a href="#cncr70032-sup-0001" class="usa-link">S7B,C</a>). On stratifying by the type of induction therapy, LIT + VEN improved the median OS compared to LIT alone in the <em>NPM1</em>
<sup>mut</sup>/<em>FLT3</em>‐TKD<sup>wt</sup> cohort (median OS, 56 months [95% CI, 15 months to NR] vs. 11.5 months [95% CI, 5.6–16 months], respectively; 3‐year OS, 59% vs. 26%, respectively; HR, 0.5; 95% CI, 0.3–0.8; <em>p</em> = .004; see Figure <a href="#cncr70032-sup-0001" class="usa-link">S7</a>A).</p>
<p>In the LIT <em>NPM1</em>
<sup>mut</sup>/<em>FLT3</em>‐TKD<sup>wt</sup> AML cohort (<em>n</em> = 80), eight patients (10%) underwent ASCT in first remission, with median time to ASCT of 5.4 months (range, 2.7–9.0 months). For these patients, the median age was 68.5 years (range, 62–72 years). On landmark analysis, there was no OS benefit with ASCT (3‐year OS, 75% vs. 62% without ASCT; <em>p</em> = .2).</p>
<p>When comparing the current <em>NPM1</em>
<sup>mut</sup>/<em>FLT3</em>‐TKD<sup>wt</sup> cohort with our previous <em>NPM1</em>
<sup>mut</sup>/<em>FLT3</em>‐TKD<sup>mut</sup> cohort (<em>n</em> = 31), as mentioned above, there was no statistically significant difference in OS (3‐year OS, 40% vs. 32%, respectively) or EFS (log‐rank <em>p</em> = .9 and <em>p</em> = .7, respectively; see Figure <a href="#cncr70032-sup-0001" class="usa-link">S7B,C</a>).</p></section></section></section><section id="cncr70032-sec-0150"><h2 class="pmc_sec_title">DISCUSSION</h2>
<p>We describe one of the largest cohorts of patients with newly diagnosed <em>FLT3‐</em>TKD<sup>mut</sup> AML, with particular focus on the effect of <em>NPM1</em> co‐mutation and the impact of contemporary therapies including, VEN and FLT3i drugs. Consistent with prior studies, <em>NPM1</em> was commonly co‐mutated in our <em>FLT3</em>‐TKD<sup>mut</sup> AML cohort, with an <em>NPM1</em> co‐mutation in 44%, and was associated with an improved overall prognosis. The occurrence of <em>NPM1</em> mutations in our cohort with <em>FLT3‐</em>TKD<sup>mut</sup> AML was associated with higher CRc rates from IC (100% vs. 67%; <em>p</em> = .001) and a trend toward higher CRc rates from LIT (74% vs. 54%; <em>p</em> = .09) compared with patients who did not have <em>NPM1</em> co‐mutation. This translated into improved OS across both patients who received IC (3‐year OS, 74% vs. 40%; <em>p</em> = .03) and those who received LIT (3‐year OS, 32% vs. 16%; <em>p</em> = .04). It is important to highlight that <em>FLT3‐</em>TKD<sup>mut</sup> AML without an <em>NPM1</em> co‐mutation was associated with particularly poor outcomes, with a median OS of only 13.8 months with IC regimens and 6.0 months with LIT regimens. It is noteworthy that such patients without co‐mutation also had enrichment of high‐risk features at baseline, such as secondary AML and adverse‐risk cytogenetics/mutations, which could partially explain the poorer prognosis.</p>
<p>The presence of <em>NPM1</em> co‐mutation in <em>FLT3‐</em>TKD<sup>mut</sup> AML also has been associated with a good prognosis in prior publications. A study by Bacher et al. in 2008 noted that the survival outcomes of patients with <em>FLT3</em>‐TKD<sup>mut</sup>/<em>NPM1</em>
<sup>mut</sup> AML were better than either mutation occurring independently (<em>FLT3</em>‐TKD<sup>mut</sup>/<em>NPM1</em>
<sup>wt</sup> and <em>NPM1</em>
<sup>mut</sup>/<em>FLT3</em>‐TKD<sup>wt</sup> AML), indicating what those authors labeled a <em>cooperative positive interaction</em> between the two mutations.<a href="#cncr70032-bib-0010" class="usa-link" aria-describedby="cncr70032-bib-0010">
<sup>10</sup>
</a> Another study from our group at MDACC in 2017 similarly demonstrated a superior OS in <em>FLT3</em>‐TKD<sup>mut</sup>/<em>NPM1</em>
<sup>mut</sup> AML compared with <em>FLT3</em>‐TKD<sup>mut</sup>/<em>NPM1</em>
<sup>wt</sup> AML.<a href="#cncr70032-bib-0011" class="usa-link" aria-describedby="cncr70032-bib-0011">
<sup>11</sup>
</a>
</p>
<p>Although our data indicate that <em>NPM1</em> co‐mutation status may positively influence prognosis in <em>FLT3</em>‐TKD<sup>mut</sup> AML, the reverse did not hold true in our analysis as opposed to that seen by Bacher et al. Compared with patients who had <em>NPM1</em>
<sup>mut</sup>/<em>FLT3</em>‐TKD<sup>wt</sup> AML, the dual‐mutant (<em>NPM1</em>
<sup>mut</sup>/<em>FLT3</em>‐TKD<sup>mut</sup>) patients did not have significantly different OS or EFS with either IC‐based or LIT‐based approaches. Therefore, the presence of <em>FLT3</em>‐TKD mutation did not appear to positively influence prognosis further in <em>NPM1</em>
<sup>mut</sup> AML but, rather, had a neutral impact in our analysis.</p>
<p>Next, we investigated how the incorporation of VEN and/or an FLT3i to IC or LIT regimens influenced outcomes in patients with <em>FLT3‐</em>TKD<sup>mut</sup> AML. In the IC group, the addition of VEN led to a CRc rate of 94%, with improved EFS (3‐year EFS, 74% vs. 35%; <em>p</em> = .03) and a trend toward improved OS (3‐year OS, 74% vs. 42%; <em>p</em> = .07) compared with patients who received IC alone (without VEN). The addition of an FLT3i to IC also appeared to lead to longer EFS and OS, although this was not statistically significant, possibly because of the smaller numbers in this comparison. These data suggest that the addition of VEN or an FLT3i (especially VEN) to IC may improve outcomes in newly diagnosed patients with IC‐eligible <em>FLT3</em>‐TKD<sup>mut</sup> AML.</p>
<p>In the LIT group, the addition of VEN led to high response rates (CRc rate, 78%) and a trend toward improved OS and EFS, although this was not statistically significant. This finding of a beneficial impact of incorporating VEN into IC or LIT regimens in <em>FLT3</em>‐TKD<sup>mut</sup> AML is not entirely novel. It was demonstrated previously that IC with VEN regimens is highly effective in the frontline setting of newly diagnosed AML across numerous molecular and cytogenetic subsets, including patients with <em>FLT3</em>‐TKD<sup>mut</sup> AML, as previously published by our group.<a href="#cncr70032-bib-0021" class="usa-link" aria-describedby="cncr70032-bib-0021">
<sup>21</sup>
</a>, <a href="#cncr70032-bib-0022" class="usa-link" aria-describedby="cncr70032-bib-0022">
<sup>22</sup>
</a>, <a href="#cncr70032-bib-0023" class="usa-link" aria-describedby="cncr70032-bib-0023">
<sup>23</sup>
</a> Furthermore, the addition of VEN to HMA led to higher CRc rates (77% vs. 30%) and improved median OS (19.2 vs. 10 months) versus placebo with HMA among newly diagnosed patients with <em>FLT3</em>‐TKD<sup>mut</sup> AML in the VIALE‐A study (ClinicalTrials.gov identifier <a href="https://clinicaltrials.gov/ct2/show/NCT02993523" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02993523</a>).<a href="#cncr70032-bib-0024" class="usa-link" aria-describedby="cncr70032-bib-0024">
<sup>24</sup>
</a>, <a href="#cncr70032-bib-0025" class="usa-link" aria-describedby="cncr70032-bib-0025">
<sup>25</sup>
</a> Prospective randomized studies are ongoing (HOVON 501; EudraCT 2020‐004453‐71) and will hopefully confirm these observations from single‐arm studies. The 13 patients with <em>FLT3</em>‐TKD<sup>mut</sup> AML in our LIT group who received triplet therapy (HMA, VEN, and FLT3i) had an impressive CRc rate of 85%, with a trend toward improved EFS compared with LIT alone (without VEN or FLT3i), but not compared with HMA + VEN, based on current follow‐up. Although highly interesting, the numbers and follow‐up of frontline, triplet‐treated patients who have AML (especially with <em>FLT3</em>‐TKD mutations) are relatively small and not sufficient to make definitive conclusions at this time.</p>
<p>We also studied the role of ASCT in <em>FLT3‐</em>TKD<sup>mut</sup> AML. The <em>FLT3‐</em>TKD<sup>mut</sup> patients who did not have an <em>NPM1</em> co‐mutation appeared to benefit the most from ASCT in first remission, with a significant improvement in OS compared with those who did not proceed to ASCT in the IC cohort and a trend toward improved OS in the LIT cohort. We believe that, currently, ASCT in first remission still should be recommended for such patients if they are otherwise candidates for ASCT. Conversely, the role of ASCT in <em>FLT3‐</em>TKD<sup>mut</sup> AML with <em>NPM1</em> co‐mutation was less clear. In both our IC cohort and our LIT cohort, such patients with <em>FLT3‐</em>TKD<sup>mut</sup>/<em>NPM1</em>
<sup>mut</sup> AML who underwent ASCT in first remission did not have an OS benefit compared with those who did not undergo ASCT. Although a smaller sample size also potentially may be contributing to these results, we believe that role of ASCT in these patients needs to be studied further, and decisions regarding ASCT need to be made on an individualized basis. High‐sensitivity <em>NPM1</em> measurable residual disease testing by reverse transcriptase‐quantitative polymerase chain reaction, NGS, and polymerase chain reaction analysis–NGS approaches are increasingly becoming available and may help identify and further refine which frontline patients with <em>NPM1</em>
<sup>mut</sup> AML are likely to benefit from ASCT in first CR.<a href="#cncr70032-bib-0026" class="usa-link" aria-describedby="cncr70032-bib-0026">
<sup>26</sup>
</a>, <a href="#cncr70032-bib-0027" class="usa-link" aria-describedby="cncr70032-bib-0027">
<sup>27</sup>
</a> Such measurable residual disease data are currently being generated on this cohort, and we hope to present them in a future analysis.</p>
<p>To the best of our knowledge, this is one of the largest analyses to date of frontline patients with <em>FLT3‐</em>TKD<sup>mut</sup> AML, the first to report outcomes of <em>FLT3‐</em>TKD<sup>mut</sup> AML with contemporary therapeutic regimens incorporating VEN or FLT3I drugs, and the first to discuss the role of ASCT in this population, especially in the context of key biologic <em>NPM1</em> co‐mutation. Our study is limited by its retrospective nature and includes only patients from a single institution. In addition, patients received various different anthracycline‐cytarabine backbone‐based induction regimens based on the availability of frontline clinical trials or off‐trial regimens at the time of diagnosis. Finally, the sample sizes for some of the subgroup analyses, particularly those comparing different therapeutic regimens, are small given the relative infrequency of <em>FLT3</em>‐TKD mutations in AML and may be underpowered for meaningful statistical comparisons. These results ideally need to be confirmed in future larger, multicenter, retrospective, and possibly prospective studies. Readers should interpret the study results within the context of these limitations.</p></section><section id="cncr70032-sec-0160"><h2 class="pmc_sec_title">CONCLUSIONS</h2>
<p>In conclusion, <em>FLT3‐</em>TKD<sup>mut</sup> AML commonly harbors <em>NPM1</em> co‐mutation, which has key prognostic implications. Lack of <em>NPM1</em> co‐mutation portends a poor prognosis in frontline <em>FLT3‐</em>TKD<sup>mut</sup> AML, with lower response rates and inferior OS to both IC and LIT. Furthermore, the utility of ASCT in <em>FLT3‐</em>TKD<sup>mut</sup> AML may also depend on <em>NPM1</em> mutational status, with a clear OS benefit from ASCT observed in patients with <em>NPM1</em>‐nonmutated AML, but not in those with <em>NPM1</em> co‐mutation.</p></section><section id="cncr70032-sec-0170"><h2 class="pmc_sec_title">AUTHOR CONTRIBUTIONS</h2>
<p>
<strong>Sankalp Arora</strong>: Conceptualization; writing—original draft; writing—review and editing; formal analysis; investigation; and methodology. <strong>Wei‐Ying Jen</strong>: Conceptualization; writing—review and editing; investigation; and formal analysis. <strong>Musa Yilmaz</strong>: Writing—review and editing. <strong>Indraneel Deshmukh</strong>: Visualization; formal analysis; investigation; and writing—review and editing. <strong>Jayastu Senapati</strong>: Writing—review and editing. <strong>Sanam Loghavi</strong>: Methodology and writing—review and editing. <strong>Ghayas C. Issa</strong>: Writing—review and editing. <strong>Nicholas J. Short</strong>: Writing—review and editing. <strong>Tapan M. Kadia</strong>: Writing—review and editing. <strong>Courtney D. DiNardo</strong>: Writing—review and editing. <strong>Gautam Borthakur</strong>: Writing—review and editing. <strong>Joseph Jabbour</strong>: Writing—review and editing and formal analysis. <strong>Naveen Pemmaraju</strong>: Writing—review and editing. <strong>Michael Andreeff</strong>: Writing—review and editing. <strong>Koichi Takahashi</strong>: Writing—review and editing. <strong>Kapil Bhalla</strong>: Writing—review and editing. <strong>Uday Popat</strong>: Writing—review and editing. <strong>Elizabeth J. Shpall</strong>: Writing—review and editing. <strong>Betul Oran</strong>: Writing—review and editing. <strong>Hussein A. Abbas</strong>: Writing—review and editing. <strong>Guillermo Garcia‐Manero</strong>: Writing—review and editing. <strong>Farhad Ravandi</strong>: Writing—review and editing. <strong>Hagop Kantarjian</strong>: Writing—review and editing. <strong>Naval Daver</strong>: Conceptualization; methodology; investigation; validation; formal analysis; supervision; resources; and writing—review and editing.</p></section><section id="cncr70032-sec-0190"><h2 class="pmc_sec_title">CONFLICT OF INTEREST STATEMENT</h2>
<p>Sanam Loghavi reports grants/contracts from Amgen and Astellas Pharma; personal/consulting fees from AbbVie, AlphaSight, Aptitude Health, Arima, Blueprint Medicine, Bristol Myers Squibb Company, Caris Diagnostics, Daiichi Sankyo Company, Gerson Lehrman Group, Guidepoint, Kura Oncology, Opinion Health, Qiagen Inc., QualWorld, Recordati Rare Diseases Inc., Servier Affaires Medicales, Stemline Therapeutics Inc., Syndax, and Tempus; and owns stock in AbbVie and PureTech outside the submitted work. Ghayas Issa reports personal/consulting fees from Novartis, Sanofi, and Syndax and data and safety monitoring for Novartis outside the submitted work. Nicholas J. Short reports grants/contracts and research funding from Ascentage, Astellas Pharma Inc., GlaxoSmithKline, Hemogenyx, NextCure, Novartis, Stemline Therapeutics Inc., Takeda Oncology, Vironexis and Xencor; personal/consulting fees from Adaptive Biotechnologies, Amgen, Autolus, GlaxoSmithKline, Novartis, PFIZER CANADA INC., and Pfizer Inc.; and honoraria from Adaptive Biotechnologies, Amgen, Astellas Pharma Inc., Pfizer Inc., Sanofi, and Takeda Oncology outside the submitted work. Tapan Kadia reports grants/contracts from Ascentage Pharma, Bristol Myers Squibb Company, Genentech, Incyte Corporation, and Jazz Pharmaceuticals; and personal/consulting fees from AbbVie, Agios Pharmaceuticals Inc., Daiichi Sankyo Company, Genentech, Novartis, Servier Pharmaceuticals, and Syndax outside the submitted work. Courtney D. DiNardo reports grants/contracts and research funding from AbbVie, Astex, BeiGene, Bristol Myers Squibb Company, Foghorn, ImmuneOnc, Remix Rigel, Servier, and Schrodinger; personal/consulting fees from AbbVie, Astellas Pharma Inc., AstraZeneca BeiGene, Bristol Myers Squibb Company, Genmab, GlaxoSmithKline, Molecular Partners, Ryvu, Schrodinger, Servier, and Stemline; honoraria from AbbVie, Astellas Pharma Inc., Bristol Myers Squibb Company, Jazz Pharmaceuticals, and Servier; support for attending meetings/travel from Servier; and service on a Data Safety Board at Genmab outside the submitted work. Naveen Pemmaraju reports grants/contracts from the US Department of Defense; personal/consulting fees from AbbVie, Bristol Myers Squibb Company, GSK Consulting, Immunogen, Incyte Corporation, Johnson &amp; Johnson, Karyopharm Therapeutics, Morphosys, OPNA, Protagonist Therapeutics, Sobi, Takeda Oncology, and Total CME; and support for other professional activities from CTI BioPharma, Dan's House of Hope, Menarini Group, and Payclex outside the submitted work. Koichi Takahashi reports grants/contracts from Astex and Jazz Pharmaceuticals; personal/consulting fees from Meiji Seika Pharma and Symbio Pharmaceuticals; honoraria from Amgen, Illumina, Mission Bio, Otsuka Pharmaceutical, and Pfizer; and travel support from Amgen outside the submitted work. Uday Popat reports research support from Bayer Healthcare and personal/consulting fees from Daiichi Sankyo Company outside the submitted work. Elizabeth J. Shpall reports research support from FibroBiologics and Zelluna Immunotherapy; personal/consulting or advisory fees from AdaptImmune Unlimited, AxioMed LLC, Celaid Therapeutics, Cimeio Therapeutics AG, Navan Technologies, New York Blood Center, and Zelluna Immunotherapy; support for other professional activities from Dava Oncology LP, FibroBiologics, and Navan Technologies; and royalties/licenses from Affimed, RegeNexus, Syena, and Takeda Oncology outside the submitted work. Hussein A. Abbas reports research support from Ascentage, Blueprint Medicines, Genentech, Enzyme‐By‐Design, Genentech, GlaxoSmithKline, and Illumina; personal/consulting or advisory fees from Cogent Biosciences and Molecular Partners; honoraria from Alamar Biotechnology and Illumina; and in‐kind support from Illumina outside the submitted work. Farhad Ravandi reports grants/contracts from Bristol Myers Squibb Company and Taiho Pharmaceutical; personal/consulting fees from Amgen, Astellas Pharma, Bristol Myers Squibb Company, Celgene Corporation, Novartis Foundation, and Taiho Pharmaceutical; and support for other professional activities from Celgene Corporation outside the submitted work. Hagop Kantarjian reports institutional grants from AbbVie, Amgen, Ascentage, Bristol Myers Squibb Company, Daiichi Sankyo Company, Immunogen, and Novartis; personal/consulting fees from AbbVie, Amgen, Ascentage, Ipsen Biopharmaceuticals, KAHR Medical, Novartis, Pfizer, Shenzhen Target Rx, Stemline, and Takeda Oncology outside the submitted work. Naval Daver reports grants/contracts from AbbVie Inc., Amgen, Astellas Pharma, Bristol Myers Squibb Company, Daiichi Sankyo Company, FATE Therapeutics, Genentech, Gilead Sciences Inc., Glycomimetics, Hanmi, ImmunoGen Inc., Kite Pharma Inc., Novimmune, Pfizer Inc., Servier Pharmaceuticals LLC, Trillium, and Trovagene; and personal/consulting fees from AbbVie, Agios Pharmaceuticals Inc., Amgen, Arog Pharmaceuticals, Astellas Pharma, Bristol Myers Squibb Company, Celgene, Daiichi Sankyo Company, Genentech, Gilead Sciences Inc., ImmunoGen Inc., Jazz Pharmaceuticals, Kite Pharma Inc., Novartis, Pfizer Inc., Servier Pharmaceuticals LLC, Shattuck Labs, Stemline/Menarini, Syndax, and Trillium outside the submitted work. The remaining authors disclosed no conflicts of interest.</p></section><section id="sec23"><h2 class="pmc_sec_title">Supporting information</h2>
<section class="sm xbox font-sm" id="cncr70032-sup-0001"><div class="caption p"><p>Supplementary Material</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12335293/bin/CNCR-131-e70032-s001.docx" data-ga-action="click_feat_suppl" class="usa-link">CNCR-131-e70032-s001.docx</a><sup> (820.7KB, docx) </sup>
</div></div></section></section><section id="cncr70032-sec-0180" class="ack"><h2 class="pmc_sec_title">ACKNOWLEDGMENTS</h2>
<p>BioRender.com was used to create Figure <a href="#cncr70032-fig-0001" class="usa-link">1</a> (Consolidated Standards of Reporting Trials [CONSORT] diagram; permission to publish available upon request). This research is supported in part by The University of Texas MD Anderson Cancer Center Leukemia Specialized Programs of Research Excellence (SPORE Grant CA1100632) and by The University of Texas MD Anderson Cancer Center (Grant CA016672).</p></section><section id="notes1"><p>

Arora S, Jen W‐Y, Yilmaz M, et al. Outcomes of patients with newly diagnosed acute myeloid leukemia with <em>FLT3</em>‐tyrosine kinase domain mutations: prognostic implications of <em>NPM1</em> co‐mutation. Cancer. 2025;e70032. doi: 10.1002/cncr.70032

</p>
<section id="fn-group1" class="fn-group"><div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="cncr70032-note-0001"><p>This study was presented as an abstract at the 66th American Society of Hematology Annual Meeting and Exposition (ASH 2024); December 7–10, 2024; San Diego, California.</p></div>
<div class="fn p" id="cncr70032-note-0002"><p>The first two authors contributed equally to this article.</p></div>
</div></section></section><section id="cncr70032-sec-0210"><h2 class="pmc_sec_title">DATA AVAILABILITY STATEMENT</h2>
<p>De‐identified clinical data can be procured from the corresponding author at reasonable request.</p></section><section id="cncr70032-bibl-0001" class="ref-list"><h2 class="pmc_sec_title">REFERENCES</h2>
<section id="cncr70032-bibl-0001_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="cncr70032-bib-0001">
<span class="label">1.</span><cite>
Rosnet O, Schiff C, Pébusque MJ, et al. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood. 1993;82(4):1110‐1119. doi: 10.1182/blood.v82.4.1110.1110

</cite> [<a href="https://doi.org/10.1182/blood.v82.4.1110.1110" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8394751/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Human%20FLT3/FLK2%20gene:%20cDNA%20cloning%20and%20expression%20in%20hematopoietic%20cells&amp;author=O%20Rosnet&amp;author=C%20Schiff&amp;author=MJ%20P%C3%A9busque&amp;volume=82&amp;issue=4&amp;publication_year=1993&amp;pages=1110-1119&amp;pmid=8394751&amp;doi=10.1182/blood.v82.4.1110.1110&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70032-bib-0002">
<span class="label">2.</span><cite>
Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752‐1759. doi: 10.1182/blood.v98.6.1752

</cite> [<a href="https://doi.org/10.1182/blood.v98.6.1752" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11535508/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=The%20presence%20of%20a%20FLT3%20internal%20tandem%20duplication%20in%20patients%20with%20acute%20myeloid%20leukemia%20(AML)%20adds%20important%20prognostic%20information%20to%20cytogenetic%20risk%20group%20and%20response%20to%20the%20first%20cycle%20of%20chemotherapy:%20analysis%20of%20854%20patients%20from%20the%20United%20Kingdom%20Medical%20Research%20Council%20AML%2010%20and%2012%20trials&amp;author=PD%20Kottaridis&amp;author=RE%20Gale&amp;author=ME%20Frew&amp;volume=98&amp;issue=6&amp;publication_year=2001&amp;pages=1752-1759&amp;pmid=11535508&amp;doi=10.1182/blood.v98.6.1752&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70032-bib-0003">
<span class="label">3.</span><cite>
Fenski R, Flesch K, Serve S, et al. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br J Haematol. 2000;108(2):322‐330. doi: 10.1046/j.1365-2141.2000.01831.x

</cite> [<a href="https://doi.org/10.1046/j.1365-2141.2000.01831.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10691863/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Haematol&amp;title=Constitutive%20activation%20of%20FLT3%20in%20acute%20myeloid%20leukaemia%20and%20its%20consequences%20for%20growth%20of%2032D%20cells&amp;author=R%20Fenski&amp;author=K%20Flesch&amp;author=S%20Serve&amp;volume=108&amp;issue=2&amp;publication_year=2000&amp;pages=322-330&amp;pmid=10691863&amp;doi=10.1046/j.1365-2141.2000.01831.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70032-bib-0004">
<span class="label">4.</span><cite>
Sritana N, Auewarakul CU. KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups. Exp Mol Pathol. 2008;85(3):227‐231. doi: 10.1016/j.yexmp.2008.09.004

</cite> [<a href="https://doi.org/10.1016/j.yexmp.2008.09.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18977345/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Exp%20Mol%20Pathol&amp;title=KIT%20and%20FLT3%20receptor%20tyrosine%20kinase%20mutations%20in%20acute%20myeloid%20leukemia%20with%20favorable%20cytogenetics:%20two%20novel%20mutations%20and%20selective%20occurrence%20in%20leukemia%20subtypes%20and%20age%20groups&amp;author=N%20Sritana&amp;author=CU%20Auewarakul&amp;volume=85&amp;issue=3&amp;publication_year=2008&amp;pages=227-231&amp;pmid=18977345&amp;doi=10.1016/j.yexmp.2008.09.004&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70032-bib-0005">
<span class="label">5.</span><cite>
Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299‐312. doi: 10.1038/s41375-018-0357-9

</cite> [<a href="https://doi.org/10.1038/s41375-018-0357-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6365380/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30651634/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Targeting%20FLT3%20mutations%20in%20AML:%20review%20of%20current%20knowledge%20and%20evidence&amp;author=N%20Daver&amp;author=RF%20Schlenk&amp;author=NH%20Russell&amp;author=MJ%20Levis&amp;volume=33&amp;issue=2&amp;publication_year=2019&amp;pages=299-312&amp;pmid=30651634&amp;doi=10.1038/s41375-018-0357-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70032-bib-0006">
<span class="label">6.</span><cite>
Rombouts WJ, Blokland I, Löwenberg B, Ploemacher RE. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia. 2000;14(4):675‐683. doi: 10.1038/sj.leu.2401731

</cite> [<a href="https://doi.org/10.1038/sj.leu.2401731" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10764154/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Biological%20characteristics%20and%20prognosis%20of%20adult%20acute%20myeloid%20leukemia%20with%20internal%20tandem%20duplications%20in%20the%20Flt3%20gene&amp;author=WJ%20Rombouts&amp;author=I%20Blokland&amp;author=B%20L%C3%B6wenberg&amp;author=RE%20Ploemacher&amp;volume=14&amp;issue=4&amp;publication_year=2000&amp;pages=675-683&amp;pmid=10764154&amp;doi=10.1038/sj.leu.2401731&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70032-bib-0007">
<span class="label">7.</span><cite>
Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454‐464. doi: 10.1056/nejmoa1614359

</cite> [<a href="https://doi.org/10.1056/nejmoa1614359" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5754190/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28644114/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Midostaurin%20plus%20chemotherapy%20for%20acute%20myeloid%20leukemia%20with%20a%20FLT3%20mutation&amp;author=RM%20Stone&amp;author=SJ%20Mandrekar&amp;author=BL%20Sanford&amp;volume=377&amp;issue=5&amp;publication_year=2017&amp;pages=454-464&amp;pmid=28644114&amp;doi=10.1056/nejmoa1614359&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70032-bib-0008">
<span class="label">8.</span><cite>
Daver N, Venugopal S, Ravandi F. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. Blood Cancer J. 2021;11(5):104. doi: 10.1038/s41408-021-00495-3

</cite> [<a href="https://doi.org/10.1038/s41408-021-00495-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8159924/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34045454/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Cancer%20J&amp;title=FLT3%20mutated%20acute%20myeloid%20leukemia:%202021%20treatment%20algorithm&amp;author=N%20Daver&amp;author=S%20Venugopal&amp;author=F%20Ravandi&amp;volume=11&amp;issue=5&amp;publication_year=2021&amp;pages=104&amp;pmid=34045454&amp;doi=10.1038/s41408-021-00495-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70032-bib-0009">
<span class="label">9.</span><cite>
Erba HP, Montesinos P, Kim HJ, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3‐internal‐tandem‐duplication‐positive acute myeloid leukaemia (QuANTUM‐First): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet. 2023;401(10388):1571‐1583. doi: 10.1016/s0140-6736(23)00464-6

</cite> [<a href="https://doi.org/10.1016/s0140-6736(23)00464-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37116523/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Quizartinib%20plus%20chemotherapy%20in%20newly%20diagnosed%20patients%20with%20FLT3%E2%80%90internal%E2%80%90tandem%E2%80%90duplication%E2%80%90positive%20acute%20myeloid%20leukaemia%20(QuANTUM%E2%80%90First):%20a%20randomised,%20double%E2%80%90blind,%20placebo%E2%80%90controlled,%20phase%203%20trial&amp;author=HP%20Erba&amp;author=P%20Montesinos&amp;author=HJ%20Kim&amp;volume=401&amp;issue=10388&amp;publication_year=2023&amp;pages=1571-1583&amp;pmid=37116523&amp;doi=10.1016/s0140-6736(23)00464-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70032-bib-0010">
<span class="label">10.</span><cite>
Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S. Prognostic relevance of FLT3‐TKD mutations in AML: the combination matters—an analysis of 3082 patients. Blood. 2008;111(5):2527‐2537. doi: 10.1182/blood-2007-05-091215

</cite> [<a href="https://doi.org/10.1182/blood-2007-05-091215" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17965322/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Prognostic%20relevance%20of%20FLT3%E2%80%90TKD%20mutations%20in%20AML:%20the%20combination%20matters%E2%80%94an%20analysis%20of%203082%20patients&amp;author=U%20Bacher&amp;author=C%20Haferlach&amp;author=W%20Kern&amp;author=T%20Haferlach&amp;author=S%20Schnittger&amp;volume=111&amp;issue=5&amp;publication_year=2008&amp;pages=2527-2537&amp;pmid=17965322&amp;doi=10.1182/blood-2007-05-091215&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70032-bib-0011">
<span class="label">11.</span><cite>
Boddu P, Kantarjian H, Borthakur G, et al. Co‐occurrence of FLT3‐TKD and NPM1 mutations defines a highly favorable prognostic AML group. Blood Adv. 2017;1(19):1546‐1550. doi: 10.1182/bloodadvances.2017009019

</cite> [<a href="https://doi.org/10.1182/bloodadvances.2017009019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5728474/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29296796/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Adv&amp;title=Co%E2%80%90occurrence%20of%20FLT3%E2%80%90TKD%20and%20NPM1%20mutations%20defines%20a%20highly%20favorable%20prognostic%20AML%20group&amp;author=P%20Boddu&amp;author=H%20Kantarjian&amp;author=G%20Borthakur&amp;volume=1&amp;issue=19&amp;publication_year=2017&amp;pages=1546-1550&amp;pmid=29296796&amp;doi=10.1182/bloodadvances.2017009019&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70032-bib-0012">
<span class="label">12.</span><cite>
Perry M, Bertoli S, Rocher C, et al. FLT3‐TKD mutations associated with NPM1 mutations define a favorable‐risk group in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2018;18(12):e545‐e550. doi: 10.1016/j.clml.2018.06.006

</cite> [<a href="https://doi.org/10.1016/j.clml.2018.06.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30082225/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Lymphoma%20Myeloma%20Leuk&amp;title=FLT3%E2%80%90TKD%20mutations%20associated%20with%20NPM1%20mutations%20define%20a%20favorable%E2%80%90risk%20group%20in%20patients%20with%20acute%20myeloid%20leukemia&amp;author=M%20Perry&amp;author=S%20Bertoli&amp;author=C%20Rocher&amp;volume=18&amp;issue=12&amp;publication_year=2018&amp;pages=e545-e550&amp;pmid=30082225&amp;doi=10.1016/j.clml.2018.06.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70032-bib-0013">
<span class="label">13.</span><cite>
Li S, Li N, Chen Y, Zheng Z, Guo Y. FLT3‐TKD in the prognosis of patients with acute myeloid leukemia: a meta‐analysis. Front Oncol. 2023;13:1086846. doi: 10.3389/fonc.2023.1086846

</cite> [<a href="https://doi.org/10.3389/fonc.2023.1086846" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9982020/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36874106/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Oncol&amp;title=FLT3%E2%80%90TKD%20in%20the%20prognosis%20of%20patients%20with%20acute%20myeloid%20leukemia:%20a%20meta%E2%80%90analysis&amp;author=S%20Li&amp;author=N%20Li&amp;author=Y%20Chen&amp;author=Z%20Zheng&amp;author=Y%20Guo&amp;volume=13&amp;publication_year=2023&amp;pages=1086846&amp;pmid=36874106&amp;doi=10.3389/fonc.2023.1086846&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70032-bib-0014">
<span class="label">14.</span><cite>
US Food and Drug Administration (FDA)
. Resources for Information, Approved Drugs: Midostaurin. FDA; 2017. Accessed May 15, 2025. <a href="https://www.fda.gov/drugs/resources-information-approved-drugs/midostaurin" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.fda.gov/drugs/resources‐information‐approved‐drugs/midostaurin</a>
</cite> [<a href="https://scholar.google.com/scholar_lookup?title=Resources%20for%20Information,%20Approved%20Drugs:%20Midostaurin&amp;publication_year=2017&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70032-bib-0015">
<span class="label">15.</span><cite>
US Food and Drug Administration (FDA)
. FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia. FDA; 2020. Accessed May 15, 2025. <a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-venetoclax-combination-untreated-acute-myeloid-leukemia" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.fda.gov/drugs/resources‐information‐approved‐drugs/fda‐grants‐regular‐approval‐venetoclax‐combination‐untreated‐acute‐myeloid‐leukemia</a>
</cite> [<a href="https://scholar.google.com/scholar_lookup?title=FDA%20grants%20regular%20approval%20to%20venetoclax%20in%20combination%20for%20untreated%20acute%20myeloid%20leukemia&amp;publication_year=2020&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70032-bib-0016">
<span class="label">16.</span><cite>
Lin P, Jones D, Medeiros LJ, Chen W, Vega‐Vazquez F, Luthra R. Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia. Am J Clin Pathol. 2006;126(4):530‐533. doi: 10.1309/jt5b-e2l1-fgg8-p8y6

</cite> [<a href="https://doi.org/10.1309/jt5b-e2l1-fgg8-p8y6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16938665/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Clin%20Pathol&amp;title=Activating%20FLT3%20mutations%20are%20detectable%20in%20chronic%20and%20blast%20phase%20of%20chronic%20myeloproliferative%20disorders%20other%20than%20chronic%20myeloid%20leukemia&amp;author=P%20Lin&amp;author=D%20Jones&amp;author=LJ%20Medeiros&amp;author=W%20Chen&amp;author=F%20Vega%E2%80%90Vazquez&amp;volume=126&amp;issue=4&amp;publication_year=2006&amp;pages=530-533&amp;pmid=16938665&amp;doi=10.1309/jt5b-e2l1-fgg8-p8y6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70032-bib-0017">
<span class="label">17.</span><cite>
Luthra R, Patel KP, Reddy NG, et al. Next‐generation sequencing‐based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica. 2014;99(3):465‐473. doi: 10.3324/haematol.2013.093765

</cite> [<a href="https://doi.org/10.3324/haematol.2013.093765" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3943309/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24142997/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Haematologica&amp;title=Next%E2%80%90generation%20sequencing%E2%80%90based%20multigene%20mutational%20screening%20for%20acute%20myeloid%20leukemia%20using%20MiSeq:%20applicability%20for%20diagnostics%20and%20disease%20monitoring&amp;author=R%20Luthra&amp;author=KP%20Patel&amp;author=NG%20Reddy&amp;volume=99&amp;issue=3&amp;publication_year=2014&amp;pages=465-473&amp;pmid=24142997&amp;doi=10.3324/haematol.2013.093765&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70032-bib-0018">
<span class="label">18.</span><cite>
Ok CY, Loghavi S, Sui D, et al. Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia. Haematologica. 2019;104(2):305‐311. doi: 10.3324/haematol.2018.191148

</cite> [<a href="https://doi.org/10.3324/haematol.2018.191148" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6355476/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30171025/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Haematologica&amp;title=Persistent%20IDH1/2%20mutations%20in%20remission%20can%20predict%20relapse%20in%20patients%20with%20acute%20myeloid%20leukemia&amp;author=CY%20Ok&amp;author=S%20Loghavi&amp;author=D%20Sui&amp;volume=104&amp;issue=2&amp;publication_year=2019&amp;pages=305-311&amp;pmid=30171025&amp;doi=10.3324/haematol.2018.191148&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70032-bib-0019">
<span class="label">19.</span><cite>
Kadia TM, Reville PK, Wang X, et al. Phase II study of venetoclax added to cladribine plus low‐dose cytarabine alternating with 5‐azacitidine in older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2022;40(33):3848‐3857. doi: 10.1200/jco.21.02823

</cite> [<a href="https://doi.org/10.1200/jco.21.02823" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9671758/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35704787/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Phase%20II%20study%20of%20venetoclax%20added%20to%20cladribine%20plus%20low%E2%80%90dose%20cytarabine%20alternating%20with%205%E2%80%90azacitidine%20in%20older%20patients%20with%20newly%20diagnosed%20acute%20myeloid%20leukemia&amp;author=TM%20Kadia&amp;author=PK%20Reville&amp;author=X%20Wang&amp;volume=40&amp;issue=33&amp;publication_year=2022&amp;pages=3848-3857&amp;pmid=35704787&amp;doi=10.1200/jco.21.02823&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70032-bib-0020">
<span class="label">20.</span><cite>
Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642‐4649. doi: 10.1200/jco.2003.04.036

</cite> [<a href="https://doi.org/10.1200/jco.2003.04.036" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14673054/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Revised%20recommendations%20of%20the%20International%20Working%20Group%20for%20Diagnosis,%20Standardization%20of%20Response%20Criteria,%20Treatment%20Outcomes,%20and%20Reporting%20Standards%20for%20Therapeutic%20Trials%20in%20Acute%20Myeloid%20Leukemia&amp;author=BD%20Cheson&amp;author=JM%20Bennett&amp;author=KJ%20Kopecky&amp;volume=21&amp;issue=24&amp;publication_year=2003&amp;pages=4642-4649&amp;pmid=14673054&amp;doi=10.1200/jco.2003.04.036&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70032-bib-0021">
<span class="label">21.</span><cite>
DiNardo CD, Lachowiez CA, Takahashi K, et al. Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J Clin Oncol. 2021;39(25):2768‐2778. doi: 10.1200/jco.20.03736

</cite> [<a href="https://doi.org/10.1200/jco.20.03736" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8407653/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34043428/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Venetoclax%20combined%20with%20FLAG%E2%80%90IDA%20induction%20and%20consolidation%20in%20newly%20diagnosed%20and%20relapsed%20or%20refractory%20acute%20myeloid%20leukemia&amp;author=CD%20DiNardo&amp;author=CA%20Lachowiez&amp;author=K%20Takahashi&amp;volume=39&amp;issue=25&amp;publication_year=2021&amp;pages=2768-2778&amp;pmid=34043428&amp;doi=10.1200/jco.20.03736&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70032-bib-0022">
<span class="label">22.</span><cite>
Kadia TM, Reville PK, Borthakur G, et al. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high‐risk myelodysplastic syndrome: a cohort from a single‐centre, single‐arm, phase 2 trial. Lancet Haematol. 2021;8(8):e552‐e561. doi: 10.1016/s2352-3026(21)00192-7

</cite> [<a href="https://doi.org/10.1016/s2352-3026(21)00192-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8884174/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34329576/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Haematol&amp;title=Venetoclax%20plus%20intensive%20chemotherapy%20with%20cladribine,%20idarubicin,%20and%20cytarabine%20in%20patients%20with%20newly%20diagnosed%20acute%20myeloid%20leukaemia%20or%20high%E2%80%90risk%20myelodysplastic%20syndrome:%20a%20cohort%20from%20a%20single%E2%80%90centre,%20single%E2%80%90arm,%20phase%202%20trial&amp;author=TM%20Kadia&amp;author=PK%20Reville&amp;author=G%20Borthakur&amp;volume=8&amp;issue=8&amp;publication_year=2021&amp;pages=e552-e561&amp;pmid=34329576&amp;doi=10.1016/s2352-3026(21)00192-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70032-bib-0023">
<span class="label">23.</span><cite>
Lachowiez CA, Reville PK, Kantarjian H, et al. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post‐hoc, propensity score‐matched, cohort study. Lancet Haematol. 2022;9(5):e350‐e360. doi: 10.1016/s2352-3026(22)00076-x

</cite> [<a href="https://doi.org/10.1016/s2352-3026(22)00076-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9946440/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35483396/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Haematol&amp;title=Venetoclax%20combined%20with%20induction%20chemotherapy%20in%20patients%20with%20newly%20diagnosed%20acute%20myeloid%20leukaemia:%20a%20post%E2%80%90hoc,%20propensity%20score%E2%80%90matched,%20cohort%20study&amp;author=CA%20Lachowiez&amp;author=PK%20Reville&amp;author=H%20Kantarjian&amp;volume=9&amp;issue=5&amp;publication_year=2022&amp;pages=e350-e360&amp;pmid=35483396&amp;doi=10.1016/s2352-3026(22)00076-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70032-bib-0024">
<span class="label">24.</span><cite>
DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617‐629. doi: 10.1056/nejmoa2012971

</cite> [<a href="https://doi.org/10.1056/nejmoa2012971" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32786187/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Azacitidine%20and%20venetoclax%20in%20previously%20untreated%20acute%20myeloid%20leukemia&amp;author=CD%20DiNardo&amp;author=BA%20Jonas&amp;author=V%20Pullarkat&amp;volume=383&amp;issue=7&amp;publication_year=2020&amp;pages=617-629&amp;pmid=32786187&amp;doi=10.1056/nejmoa2012971&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70032-bib-0025">
<span class="label">25.</span><cite>
Konopleva M, Thirman MJ, Pratz KW, et al. Impact of FLT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment‐naive acute myeloid leukemia. Clin Cancer Res. 2022;28(13):2744‐2752. doi: 10.1158/1078-0432.ccr-21-3405

</cite> [<a href="https://doi.org/10.1158/1078-0432.ccr-21-3405" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9365380/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35063965/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Impact%20of%20FLT3%20mutation%20on%20outcomes%20after%20venetoclax%20and%20azacitidine%20for%20patients%20with%20treatment%E2%80%90naive%20acute%20myeloid%20leukemia&amp;author=M%20Konopleva&amp;author=MJ%20Thirman&amp;author=KW%20Pratz&amp;volume=28&amp;issue=13&amp;publication_year=2022&amp;pages=2744-2752&amp;pmid=35063965&amp;doi=10.1158/1078-0432.ccr-21-3405&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70032-bib-0026">
<span class="label">26.</span><cite>
Othman J, Potter N, Ivey A, et al. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood. 2024;143(19):1931‐1936. doi: 10.1182/blood.2023023096

</cite> [<a href="https://doi.org/10.1182/blood.2023023096" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38364112/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Postinduction%20molecular%20MRD%20identifies%20patients%20with%20NPM1%20AML%20who%20benefit%20from%20allogeneic%20transplant%20in%20first%20remission&amp;author=J%20Othman&amp;author=N%20Potter&amp;author=A%20Ivey&amp;volume=143&amp;issue=19&amp;publication_year=2024&amp;pages=1931-1936&amp;pmid=38364112&amp;doi=10.1182/blood.2023023096&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70032-bib-0027">
<span class="label">27.</span><cite>
Othman J, Tiong IS, O'Nions J, et al. Molecular MRD is strongly prognostic in patients with NPM1‐mutated AML receiving venetoclax‐based nonintensive therapy. Blood. 2024;143(4):336‐341. doi: 10.1182/blood.2023021579

</cite> [<a href="https://doi.org/10.1182/blood.2023021579" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37647641/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Molecular%20MRD%20is%20strongly%20prognostic%20in%20patients%20with%20NPM1%E2%80%90mutated%20AML%20receiving%20venetoclax%E2%80%90based%20nonintensive%20therapy&amp;author=J%20Othman&amp;author=IS%20Tiong&amp;author=J%20O'Nions&amp;volume=143&amp;issue=4&amp;publication_year=2024&amp;pages=336-341&amp;pmid=37647641&amp;doi=10.1182/blood.2023021579&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><p>Supplementary Material</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12335293/bin/CNCR-131-e70032-s001.docx" data-ga-action="click_feat_suppl" class="usa-link">CNCR-131-e70032-s001.docx</a><sup> (820.7KB, docx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>De‐identified clinical data can be procured from the corresponding author at reasonable request.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Cancer are provided here courtesy of <strong>Wiley</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1002/cncr.70032"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/CNCR-131-e70032.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1004.6 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12335293/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12335293/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12335293%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335293/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12335293/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12335293/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40782343/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12335293/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40782343/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12335293/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12335293/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="CG8QQ44ZVRdPhAa5NtvCdY8gARccCVQpXU8dexuJUCbQcAPLsTu6kX5SfVSjy2A9">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Web Policies

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    FOIA

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS Vulnerability Disclosure

    
</a>

                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Help

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Accessibility

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Careers

    
</a>

                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NLM

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NIH

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    USA.gov

    
</a>

                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-370d5dd6.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-917ba005.js"></script>
    
    

    </body>
</html>
